The Effect of Isocitrate Dehydrogenase on the Epigenetics of Human Mitochondrial DNA by Strang, John
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2014
The Effect of Isocitrate Dehydrogenase on the
Epigenetics of Human Mitochondrial DNA
John Strang
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Medicine and Health Sciences Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/3389
 
 
The Effect of Isocitrate Dehydrogenase on the Epigenetics of Human 
Mitochondrial DNA 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
 
 
 
by 
John Andrew Strang 
B.S. James Madison University 2012 
 
 
 
Director: Dr. Shirley M. Taylor, Ph.D. 
Associate Professor of Microbiology and Immunology 
 
 
 
 
Virginia Commonwealth University  
Richmond, Virginia 
May 2014 
  
ii 
 
Acknowledgement 
Throughout the course of completing this thesis, there are many people to thank. I would 
like to first thank my wonderful advisor Dr. Shirley Taylor without whom this thesis would not 
be possible. She was able to instill in me a drive to succeed and a passion for my research which 
I did not know I could have and to think critically in everything I do. I was pushed harder than I 
have ever been pushed before and challenged to use my mind to its utmost capacity. I was able to 
gain a series of invaluable skills in her laboratory that I will continue to nurture and build upon 
including biological techniques as well as troubleshooting abilities. With her guidance I can 
safely say that I am a better biologist and critical thinker and I thank her deeply for these new 
skills she has bestowed upon me. I am very grateful to have been allowed the opportunity to 
work in her lab and be in a great environment. While the road was not easy, I cannot imagine a 
more perfect experience than the one I was given.  
My committee members, Dr. Zendra Zehner and Dr. Masoud Manjili, also deserve a 
great deal of thanks as without them I would not be able to graduate and finish this thesis. I am 
thankful to have gotten to know them and am grateful for all the advice and insight they were 
able to give me. They provided me with a challenging set of goals to accomplish in my short 
time at Virginia Commonwealth University but I am thankful for that challenge and to be able to 
prove myself to them to the best of my abilities and even beyond.  
I would also like to thank the members of the Taylor lab, past and present, who were 
integral to my success and without whom I would not have graduated. Elliot Burton, Shannon 
Hedrick, Tim Lochmann and Prashant Thakkar were extremely helpful resources whenever I was 
confronted with a problem I could not solve. I owe each of them a large amount of gratitude and 
am happy to have been able to meet and interact with all of them. They each offered a vast 
wealth of, not only scientific knowledge, but also important lessons that I will continue to carry 
with me. I wish them each all the best success in their own careers.  
Also, I want to thank Dr. Richard Moran as well as the members of his lab including Stuti 
Agarwal, Catherine Bell, William Buchwald, Grinal Corriea, Chuck Lyons and Chen Wang who 
provided a great deal of friendship and scientific insight while I was in the lab. I am so blessed to 
have been able to meet all these new people and draw from the knowledge they possess.   
I must thank all my friends who have stood by me while I attempt the toughest obstacle 
of my life. Most importantly, I must thank my wonderful girlfriend Stephanie who I could lean 
on when times were tough and count on to help me through anything. She has pushed me to my 
breaking point and beyond and I could not ask for a better person to share my accomplishments 
with. 
Lastly, I must thank my family who has remained by my side through thick and thin. My 
younger brother, who has inspired me to continue to constantly achieve all the time and become 
as knowledgeable in my own studies as he is in his. My mother, who has never faltered in her 
support and love for me and will continue to stand by my side no matter what. Also, I must thank 
my father who, in his passing, provided me with the spark to begin a career in biology. I can 
safely say that I would not have become the man I am today without his guidance. I hope to 
make everyone I have acknowledged proud of me through this thesis and I thank each and every 
one of you for everything. This one is for you all.   
iii 
 
Table of Contents 
Acknowledgement ............................................................................................................................ii 
List of Tables ....................................................................................................................................vi 
List of Figures ...................................................................................................................................vii 
Abstract .............................................................................................................................................x 
Chapter 1: Introduction ..................................................................................................................1 
 The Study of Epigenetics in Cancer.......................................................................................1 
 The Role of Isocitrate Dehydrogenase in the Tricarboxylic Acid Cycle ...............................5 
 The Role of Isocitrate Dehyrdrogenase in Gene Expression and Cellular Differentiation ....7 
 The Human Mitochondria and its Role ..................................................................................10 
 The Warburg Hypothesis .......................................................................................................14 
 The Study of Epigenetics as it Pertains to the Mitochondria .................................................17 
Chapter 2: Materials and Methods ................................................................................................21 
 Cells, Cell culture, and plasmids used to determine the effect of IDH mutations on 
mitochondria ..........................................................................................................................21  ii 
 Transient transfection.............................................................................................................21 
 Selection of Stable Transfectants ...........................................................................................23 
 Protein Concentration Assays ................................................................................................24 
iv 
 
 Immunoblot Assays of Protein Expression ............................................................................24 
 Extracting and purifying DNA from transfected cell lines ....................................................26 
 MeDIP/Hydroxy-MeDIP Assay.............................................................................................27 
 Assessment of DNA-IPs ........................................................................................................30 
 Quantitative PCR measurement of mtDNA in DNA-IP samples ..........................................31 
 Uncovering the effect of (D)-2-hydroxyglutarate on mitochondrial epigenetics ..................32 
 Use of an IDH1 R132H Mutation Inhibitor to improve 5-hydroxymethylcytosine levels in 
the Mitochondrial Genome  ...................................................................................................32 
Chapter 3: Results............................................................................................................................34 
 The effect of IDH mutation on mitochondrial epigenetics using the HCT-116 cell line ......34 
 The effect of IDH mutations on mitochondrial epigenetics using the HEK293 cell line ......43 
 The effect of Long-Term Expression of IDH mutants ...........................................................53 
 Effect of Octyl-2-hydroxyglutarate on the 5-hydroxymethylcytosine content of the 
mitochondrial genome ...........................................................................................................57 
 Use of an IDH1 Mutation Inhibitor to Rescue 5-hydroxymethylcytosine levels ..................62 
Chapter 4: Discussion ......................................................................................................................68 
 Aberrant Metabolism in Cancer: Understanding the Warburg Effect ...................................68 
 Role of Mitochondria in disease ............................................................................................70 
v 
 
 Transcription of the Mitochondrial Genome .........................................................................73 
 Discovery of a novel oncogene: Isocitrate Dehydrogenase ...................................................75 
 The predicted role of mutant IDH in human mitochondria ...................................................78 
 The Importance of Mitochondrial Cytosine Modifications ...................................................83 
 Perspectives and Conclusions ................................................................................................85 
Literature Cited ...............................................................................................................................87 
Vita  ................................................................................................................................................97 
 
 
 
 
 
 
 
 
 
 
vi 
 
List of Tables 
Table 1: Table of expression plasmids used in this thesis .................................................................22 
Table 2: List of antibodies used for immunoblotting .........................................................................25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
List of Figures 
Figure 1-1:  Diagram representing differential patterns of methylation in normal and cancerous 
cells .................................................................................................................................3 
Figure 1-2: The Tricarboxylic Acid Cycle.........................................................................................8 
Figure 1-3: Organization of the mitochondrial genome in human cells ............................................12 
Figure 1-4: The Warburg Effect ........................................................................................................15 
Figure 1-5: p53 status affects mitochondrial gene expression in a gene-specific manner .................18 
Figure 2-1: Schematic representing the protocol used for the MeDIP/Hydroxy-MeDIP method .....28 
Figure 3-1: Determining transfection efficiency in HCT-116 cell line .............................................35 
Figure 3-2: Analysis of protein expression levels of transiently transfected HCT-116 cells using 
immunoblotting ..............................................................................................................36 
Figure 3-3: Example of endpoint PCR of HCT116 cells after transient transfection of IDH1 wild-
type plasmid .....................................................................................................................40 
Figure 3-4: Expression of mutant IDH causes a reduction in the level of 5hmC in the 12S gene of 
the mitochondrial genome ................................................................................................41 
Figure 3-5: Expression of mutant IDH causes a reduction in the level of 5hmC in the 16S gene of 
the mitochondrial genome ................................................................................................42 
Figure 3-6: Determination of Transfection Efficiency of HEK293 cells ..........................................44 
Figure 3-7: Immunoblots of transient transfection using HEK293 cell line ......................................45 
viii 
 
Figure 3-8: Sonication of purified DNA using HEK293 cells ...........................................................47 
Figure 3-9: Endpoint PCR of HEK293 cells......................................................................................48 
Figure 3-10: Analysis of epigenetic modification of the 12S rRNA gene after transfection of 
HEK293 cells with wt and mutant IDH .........................................................................51 
Figure 3-11: Analysis of epigenetic modification of the 16S rRNA gene after transfection of 
HEK293 cells with wt and mutant IDH .........................................................................52 
Figure 3-12: IDH expression levels in IDH1 mutant and wild-type stable clones ............................55 
Figure 3-13: IDH expression levels in IDH2 mutant and wild-type stable clones ............................56 
Figure 3-14: Visual representation of 12S and 16S rRNA regions after treatment with cell 
permeable 2-hydroxyglutarate ......................................................................................59 
Figure 3-15: Treatment of HEK293 cells with cell 2-hydroxyglutarate results in reduced 5hmC 
content in the mitochondrial genome .............................................................................60 
Figure 3-16: Treatment of HEK293 cells with cell 2-hydroxyglutarate results in indeterminate 
changes in 5mC content in the mitochondrial genome .................................................61 
Figure 3-17: Visual representation of 12S and 16S rRNA regions after treatment with IDH1 
mutant inhibitor ..............................................................................................................64 
Figure 3-18: Evaluation of levels of 5hmC after exposure to a specific inhibitor of mutant IDH1 ..65 
Figure 3-19: Evaluation of levels of 5mC after exposure to a specific inhibitor of mutant IDH1 ....66 
ix 
 
Figure 4-1: Diagram of oxidative phosphorylation as it occurs in normally dividing cells within 
the inner membrane of the mitochondria ...........................................................................................69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
Abstract 
 
THE EFFECTS OF ISOCITRATE DEHYDROGENASE ON HUMAN MITOCHONDRIAL 
EPIGENETICS 
By John Andrew Strang, B.S. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
Virginia Commonwealth University, 2014 
Major Director: Dr. Shirley M. Taylor, Ph.D. Associate Professor of Microbiology and 
Immunology 
Aberrant metabolism has become an increasingly interesting area of cancer biology. In 
many cancers including lower grade glioma, glioblastomas and some leukemias, a mutation in 
the metabolic enzyme Isocitrate Dehydrogenase (IDH), has been found in more than 70% of 
cases and has been shown to  lead to a distinct hypermethylator phenotype. IDH commonly 
converts isocitrate to alpha-ketoglutarate in normal cell metabolism. Three isoforms of this 
enzyme are found in humans: IDH1, IDH2 and IDH3. Studies on IDH1, the cytosolic isoform, 
have revealed that mutations in the enzyme’s binding site lead to a novel gain of function: the 
synthesis of an oncogenic metabolite, 2-hydroxyglutarate (2HG). 2HG competitively inhibits 
alpha-ketoglutarate dependent enzymes such as the TET 5-methylcytosine (5mC) oxygenases 
and histone demethylases. These oxygenases are responsible for the hydroxymethylation (5hmC) 
of cytosine residues, ultimately leading to demethylation and gene re-expression. Thus, mutant 
IDH may lead to an elevation in 5mC levels producing the hypermethylator phenotype described.  
A similar gain-of-function mutation in IDH2, the mitochondrial isoform of IDH1, has 
been associated with leukemias and gliomas lacking IDH1 mutations.  Mutations in IDH1, IDH2 
and TET2 are mutually exclusive, and each yields a similar hypermethylator phenotype.  IDH2, 
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along with IDH3, is primarily involved in the TCA cycle and energy production for the cell. 
Recently, the Taylor lab has uncovered evidence of 5mC and 5hmC residues in mitochondrial 
DNA, established and maintained by mtDNMT1 and TET2. Changing levels of mtDNMT1 
appears to alter the patterns and levels of mtDNA transcription from the mitochondrial genome.  
We hypothesized that mutant IDH would produce a similar effect on the mitochondrial genome 
as that found in the nuclear genome and result in a decrease in the level of 5-
hydroxymethylcytosine, as well as a subsequent increase in the level of 5-methylcytosine caused 
by the competitive inhibition of the TET enzymes by 2-hydroxyglutarate accumulation. Using 
molecular biology techniques such as Western blots and MeDIP (methylated DNA 
immunoprecipitation) I aim to uncover the role of IDH mutation on mitochondrial DNA 
methylation and its effect on energy production in mammalian cells.   
 
 
 
Chapter 1:  Introduction 
The Study of Epigenetics in Cancer 
Epigenetics is defined as the study of changes in gene expression independent of changes 
in the DNA sequence itself (34). These genetic changes can be passed down from generation to 
generation within a species and work to silence genes in a controlled and regulated way. 
Mammalian species have evolved multiple regulatory pathways involving epigenetics including 
the silencing of large portions of one of the X chromosomes in females during X linked 
inactivation, differentiation of stem cells during development (28), and genomic imprinting. 
Epigenetics can be subdivided into three major categories: Nucleosome remodeling, Histone 
modifications and DNA methylation (88).  
Of the three categories, DNA methylation is the most thoroughly studied. DNA 
methylation involves the transfer of a methyl group from S-adenosylmethionine (SAM) to the 
fifth carbon position of a cytosine residue in a cytosine guanosine (CpG) dinucleotide. There are 
many CpG rich areas found in the genome called “CpG islands” which are defined as areas of 
about 200 base pairs, containing an observed-to-expected CpG ratio of greater than 60%. These 
CpG rich areas comprise about 40% of the promoters in mammalian genomes (35) with more 
than 70% of human gene promoters carrying a large CpG content. Promoter CpG methylation in 
mammals ultimately leads to the repression of transcription from that promoter (39). The 
enzymes responsible for cytosine methylation in the human genome make up the family of DNA 
methyltransferases (DNMTs). There are three catalytically active DNMT isoforms in the 
mammalian genome that work to ensure that proper cytosine methylation occurs: DNMT1, 
DNMT3a and DNMT3b. DNMT1 is known as a maintenance methyltransferase and works to 
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maintain the methylation patterns of the genome during DNA replication. Both DNMT3a and 
DNMT3b work as de novo methyltransferases that place new methyl groups on cytosine residues 
when necessary such as in early development (58, 88). A catalytically inactive DNA 
methyltransferase, DNMT3L, also exists that establishes maternal genomic imprinting during 
gametogenesis (9). Another DNA methyltransferase family member, originally labeled as 
DNMT2, has been shown to mutilate the transfer RNA molecule that encodes for aspartic acid 
and is therefore functionally distinct from the other DNMTs in that it can methylate RNA (23).    
Over centuries, DNA methylation of the mammalian genome has lead to substantial CpG 
dinucleotide depletion (27). Once methylated, cytosine residues can be deaminated 
spontaneously or by activation-induced cytosine deaminase (AID) to thymine. Persistence of 
thymine in place of cytosine results in CpG to TpG mutations, and a decrease in the total amount 
of cytosine residues able to be methylated in the context of CpG dinucleotides. However, small 
areas of the genome, typically found in the promoter areas of many genes have retained close to 
the expected amount of CpG dinucleotides, largely because they are resistant to cytosine 
methylation and these areas have been designated CpG islands. In normal differentiated cells, the 
epigenome is generally described as unmethylated at these CpG island sites with concomitant 
methylation of non-island CpG dinucleotides found usually within the body of the gene (Figure 
1-1). These non-island CpG sites can also be found in repetitive areas within the genome as well 
as around inserted viral sequences and transposons which can move to different areas of the 
genome randomly. This pattern allows for ample gene transcription from the promoter start site 
and represses unwanted transcription at these irregular elements of the cellular genome which 
could do harm to the cell. In contrast to this pattern of normal gene transcription, in cancer the 
epigenetics of the cell are altered to form an entirely different pattern of CpG methylation. A  
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Figure 1-1: Diagram representing differential patterns of methylation in normal and 
cancerous cells. In normal cells, genes are characterized by hypomethylation at CpG island 
promoter regions, which account for about 40% of gene promoter areas, and CpG methylation 
within the gene body. Conversely, in cancer cells, the epigenomic pattern is marked by promoter 
CpG island hypermethylation and a subsequent hypomethylation of CpG dinucleotides within 
the gene body. Figure adapted from Herman, 2003, New England Journal of Medicine 
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 distinctive pattern is produced wherein the genome becomes globally hypomethylated with 
subsequent hypermethylation of the CpG islands found at gene promoters (63). This pattern 
generally leads to a large increase in gene transcription from normally repressed genes 
(oncogenes) and an ensuing repression of gene transcription levels from normally active genes 
(tumor suppressors). The genomic hypomethylation phenomenon can lead to greater genomic 
instability and chromosomal rearrangement which in turn can lead to the uncontrolled activation 
of growth promoting genes, such as RAS, and the loss of imprinting in many cells. This aberrant 
growth has come to be known as one of the hallmarks of cancer (25). The abnormal methylation 
pattern has become a field of intense study as epigenetic inactivation has succeeded mutational 
inactivation as the most common insult found in the cancer genome. This hypermethylation is so 
integral to the development of cancer that a distinctive phenotype, the CpG Island 
Hypermethylator phenotype (CIMP), discovered in the 1990s, was confirmed by showing that a 
subset of CpG islands is coordinately methylated in tumors (74). The subset of genes most 
commonly affected in the CIMP phenotype are those that are targets for polycomb group 
proteins which are essential for epigenetic silencing. Typically genes involved in cell cycle 
progression, apoptosis, DNA repair and growth factor response, such as Rb, caspase 8, BRCA1 
and ER respectively, are methylated so that the cell does not respond to arrest signals and 
continues to grow leading to tumorigenesis (5 and 39). The rise in oncogenes that promote 
growth and the fall in tumor suppressing genes that inhibit expansion both work to define cancer 
in many tumor types. 
Many studies have pointed to the DNA methyltransferase, DNMT1, the maintenance 
methyltransferase, as the culprit of abnormal methylation patterns during tumorigenesis (27). 
This enzyme methylates newly synthesized hemimethylated daughter strands after replication to 
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ensure stably inherited methylation of the genome from generation to generation. However, this 
enzyme interacts with the other DNMTs, the de novo methyltransferases DNMT3A and 
DNMT3B, to establish patterns of methylation and all three are required for normal embryonic 
development, making a single cause of aberrant methylation in cancer difficult to pinpoint. Other 
studies have shown that DNMTs work with histones and the chromatin surrounding CpG island 
promoters to activate and repress gene transcription. In normal cells, where promoters are 
unmethylated at CpG sites, nucleosomes are widely spaced. This spacing is achieved by histone 
tail modifications, such as acetylation of key lysine residues on histone H3, which open up the 
nucleosomes allowing access by transcription factors to the promoter for gene transcription 
activation. Contrasting this, in cancer where CpG island promoter regions are almost exclusively 
methylated, the nucleosomes are condensed prohibiting transcription factors from binding to the 
promoter region of this gene. These regions are also typically associated with histone 
deacetylases and histone methylation marks at lysine 9 of histone H3 which are typically 
indicative of gene repression and inactivation (27). The study of epigenetics is critical to 
understanding tumorigenesis and many connections between histone modifications, nucleosome 
remodeling and cytosine methylation have been made in regards to gene transcription regulation. 
It is now impossible to think of cancer without understanding epigenetic processes as well. In 
this thesis, we have focused on cytosine modifications and the relationship they play in 
transcription to alter gene expression as it relates to reprogramming metabolism. 
The Role of Isocitrate Dehydrogenase in the Tricarboxylic Acid Cycle  
Multiple enzymes of the TCA cycle have been shown to be implicated in the progression 
of cancer including Succinate Dehydrogenase (SDH) (67) and Fumarate Hydratase (FH) (31). 
These enzymes, in normal tissues, typically contribute to ATP production 
6 
 
via the TCA cycle and once mutated, such as in cancer, lead to the accumulation of metabolic 
intermediates within the cell and aberrant cellular metabolism. This build up leads to an increase 
in the production of hypoxia inducible factor α (HIFα) which works to facilitate the cell’s 
response to a hypoxic environment. This response contributes to the processes of angiogenesis, 
apoptosis and metabolism so that the cell can survive in a low-oxygen situation. With HIF1α 
constitutively expressed in cancer cells, they can continue to survive even with little oxygen, 
contributing to the Warburg effect (38). Another metabolite of interest to the scientific 
community as it relates to cancer biology is the enzyme Isocitrate Dehydrogenase or IDH.  
IDH is an enzyme of the TCA cycle (Figure 1-2) that catalyzes the oxidative 
decarboxylation of isocitrate to the metabolite α-ketoglutarate which, due to the high change in 
negative free energy associated with this reaction, has been termed an irreversible step of the 
TCA cycle and is very tightly regulated (2). Three different isoforms of this enzyme exist: IDH1, 
IDH2 and IDH3 which are all encoded by separate genes found in the nucleus. IDH3 is 
composed of two alpha chains, one beta chain and one gamma chain while both IDH1 and IDH2 
are homodimers (70). While all three isoforms catalyze the same reaction, IDH1 and IDH2 are 
able to reverse this process if need be and help to regulate the amount of α-ketoglutarate and 
NADPH pools produced within the cell (47). The isoforms are localized to different subcellular 
compartments in the cell, with both IDH2 and IDH3 contained in the mitochondria while IDH1 
is found in the cytosol and in peroxisomes. Both IDH1 and IDH2 utilize the electron acceptor 
NADP
+ 
while IDH3 uses NAD
+ 
as an electron acceptor to generate NADPH and NADH 
respectively. This reaction requires the use of a Mn
2+
 ion found in the active site of the enzyme 
which helps to stabilize the isocitrate molecule as it is converted to α-ketoglutarate through a 
highly unstable enol intermediate (Lehninger, 2008). This reaction utilizes a molecule of 
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NAD(P)
+
 which oxidizes a hydride transfer to create one molecule of NAD(P)H which can be 
used in the oxidative phosphorylation pathway found in the mitochondria. This oxidation of 
isocitrate creates the oxalosuccinate intermediate which remains in the active site of the enzyme 
where one molecule of CO2 is released. With the help of the Mn
2+
 ion, the enol intermediate is 
stabilized and converted into α-KG which can be used elsewhere in the cell. α-KG is an essential 
molecule of the TCA cycle and is required for many enzymes in relation to metabolism including 
those needed for amino acid synthesis, nitrogen transport, collagen formation and oxidation 
reactions among others. Of particularly interesting importance is the fact that α-KG is integral to 
many enzymes including a family of dioxygenases called the Ten Eleven Translocation (TET) 
family.  The effect this enzyme has on the cell is quite intriguing and was examined in this thesis 
to discern if the alterations caused by IDH reached into the mitochondrial genome where cellular 
metabolism is regulated.  
The Role of Isocitrate Dehydrogenase in Gene Expression and Cellular Differentiation 
The TET family of dioxygenases is composed of three isoforms: TET1, TET2, and TET3 
which utilize α-ketoglutarate, as well as Fe2+ and O2 to catalyze the conversion of 5-
methylcytosine to a novel base, 5-hydroxymethylcytosine (32). Little is known about this new 
DNA modification although recent research points to its possible role in DNA demethylation and 
ultimately gene re-expression (Lu and Thompson, 2012 and 24). The TET enzymes initially 
oxidize the 5-methylcytosine base to 5-hydroxymethylcytosine and further oxidize this alteration 
to 5-formylcytosine and finally 5-carboxylcytosine where it is rapidly removed from the cell by 
the enzyme Thymine DNA Glycosylase (TDG) (33,26). The TDG enzyme recognizes the 5caC 
residue as a mismatch to the usual guanosine and replaces the modified cytosine with a newly 
unmodified cytosine residue via the base excision repair machinery. It is through this mechanism  
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Figure 1-2: The Tricarboxylic Acid Cycle. Enzymes are boxed in hexagonal shapes while 
products of enzymatic reactions appear in colored ovals. By-products of each reaction are also 
displayed.  
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that DNA demethylation is possible which ultimately leads to the re-expression of genes that 
were silenced by methylation of the cytosine residues (85). Reports have uncovered that more 
than 70% of grade II and grade III gliomas, most secondary glioblastomas and even some 
instances of acute myeloid leukemia contain a somatic point mutation in the IDH1 or IDH2 
genes (87, 50), and this has been shown to lead to the distinctive CpG island methylator 
phenotype (CIMP) which is characterized by a global hypermethylation of the genome and 
defines a distinctive subgroup of gliomas (56). Patients known to contain the CIMP phenotype 
have been diagnosed earlier on in age and usually present with a more favorable prognosis than 
CIMP negative patients (12 and 52). In 2012, research discovered that, not only are the IDH 
mutation and the CIMP phenotype connected, but IDH1 mutation is sufficient to establish this 
hypermethylator phenotype in the genome of many glioma samples by disrupting DNA and 
histone methylation patterns produced in the nucleus (76). This mutation occurs at analogous 
arginine residues found in the active site of the enzymes and is a defining feature of tumor 
progression (4). One mutation, R132H is found in the IDH1 isoform while the IDH2 isoform 
most commonly contracts the R140Q or R172K mutation in these cancerous instances. Once 
originally thought to lead to a loss of IDH function, these mutations result in the loss of stability 
of the β-carboxyl of the isocitrate metabolite which is docked in the enzyme (82). Studies 
investigating both IDH1, the cytosolic isoform, and IDH2, the mitochondrial isoform, have 
revealed these mutations are heterozygous and that one wild-type allele is typically maintained 
(15, 82). This heterozygosity was predicted to confer a novel gain of function on these enzymes, 
and a neomorphic activity was demonstrated (15) leading to the synthesis of a new metabolite, 2-
hydroxyglutarate (2-HG), an analog of α-ketoglutarate. 2-HG contains a hydroxyl group at the 
carbon 2 position whereas the carbon 2 position of α-ketoglutarate has an oxygen molecule 
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bound to it. The D (-) enantiomer of 2-HG is typically produced via the IDH mutation. It is 
believed that while the wild-type allele of IDH is used to convert isocitrate into α-ketoglutarate, 
the mutant allele can use the newly synthesized metabolite, as well as NADPH, to reduce it to 2-
HG and create a molecule of NADP
+
 in the process. This new molecule, 2-HG, which is 
commonly kept at low levels below 0.1nM (47), builds up substantially within the cell and 
consequently reduces the pool of α-ketoglutarate available. Researchers have shown that the 
metabolite 2-HG competitively inhibits the active sites of enzymes, such as the TET 
dioxygenases mentioned above (86). This inhibition of the TET enzymes leads to a decrease in 
the amount of 5-hydroxymethylcytosine produced and a subsequent rise in 5-methylcytosine 
residues in the nuclear DNA of the cell which establishes a hypermethylator phenotype such as 
that described (76). Of particular note is the distribution of IDH mutations in cancer. In acute 
myeloid leukemia (AML), the IDH1 and IDH2 mutations are mutually exclusive to each other as 
well as to TET2 mutations commonly found in myeloid cancers (1, 41,16), confirming the 
hypothesis that these mutations have a similar mechanism of action to disrupt the methylation 
patterns of the cell (21). Along with the inhibition of TET enzymes, other α-ketoglutarate 
dependent enzymes are affected by this mutation including histone modifying enzymes which 
control cellular differentiation and gene expression. Experiments performed in this thesis were 
aimed at more fully understanding the far-reaching effects of mutant IDH. 
The Human Mitochondrion and its Role 
The circular double stranded mitochondrial genome is approximately 16.6 kilobases in length in 
humans and roughly 16.3 kilobases in mice (Figure 1-3). Each cell contains anywhere from 100 
to 10000 copies of mitochondrial DNA (20) and these mitochondrial genomes lack introns. Each 
strand, designated as either the heavy strand (guanosine rich) or light strand (guanosine poor), 
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encodes 28 and 9 genes respectively which, when combined, account for 13 protein coding 
genes, 22 transfer RNAs and two ribosomal RNAs. The 13 open reading frames produce 13 
proteins that are integral components of four of the five oxidative phosphorylation complexes 
necessary for energy production in the cell (79). The mitochondrial genome also contains a 
control region termed the D-loop where an origin of replication can be found as well as three 
separate transcriptional promoters. These three promoters each transcribe a specific polycistronic 
message from the mitochondrial genome. Heavy strand promoter 1 (HSP1) produces a message 
that encodes the two rRNAs, which are designated as 12S and 16S, and terminates at the end of 
the 16S gene. This termination process is dependent upon the mitochondrial transcription 
termination factor (mTERF) which creates a loop between the HSP1 promoter and the end of the 
16S gene to control the level of H1 transcript present in the cell (51). HSP2 is close to the 5’ end 
of the 12s rRNA gene and encodes the entire heavy strand. The light strand promoter (LSP) 
allows for the transcription and translation of the entire light strand of the mitochondrial genome. 
mtDNA transcription is initiated by the mitochondrial transcription factor A (TFAM), as well as 
many other factors, which work to unwind the DNA and allow for promoter recognition by the 
mitochondrial RNA polymerase (POLRMT) so that transcription can begin. Interestingly, 
mtDNA transcription functions independently of nuclear genomic transcription and can be 
initiated at different times in each mitochondrion found in the cell without any phase specificity 
meaning that not every mitochondrion is producing the same message at the same time (20). It is 
possible that this allows for greater production of necessary mitochondrial components when 
necessary in the cell.  
Evidence suggests that mitochondria play an integral role in many disease states 
including Diabetes, Alzheimer’s, Parkinson’s disease and cancer, which has led many research  
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Figure 1-3:  Organization of the mitochondrial genome in human cells. All genes encoded on 
this genome are shown as well as the start sites for the three different transcription products. The 
heavy strand is denoted in blue, the light strand denoted in black and the tRNA genes are denoted 
in red. 
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laboratories to investigate the effects of mitochondrial function and regulation in these illnesses 
(45, 66). Mitochondrial DNA is predominantly inherited via maternal inheritance in mammals 
although rare cases of paternal inheritance have been reported (Shapira, 2006). Most 
mitochondria in a cell contain the same genetic code, which is termed homoplasmy. However, 
due to the large volume of mitochondria in the cell and the generation of free oxygen radicals 
produced by the respiratory chain itself, mutations can arise much more frequently than in the 
nuclear genome. Also, during replication, different numbers of mitochondria can segregate into 
the new daughter cells produced. The coexistence of mutant and wild-type mtDNA is called 
heteroplasmy, and mutations accumulate as the individual organism ages (Shapira, 2006). 
Mitochondrial mutations commonly take the form of either a deletion or random point mutations. 
Many different mtDNA mutations have been characterized and result in debilitating pathologies 
(42). Not only are mtDNA mutations important in disease states, but mutations can also occur in 
the nuclear DNA that encodes mitochondrial proteins. Indeed, in Alzheimer’s disease, the gene 
encoding the amyloid precursor protein is mutated which leads to the impairment of oxidative 
phosphorylation processes in the cell as well as severe accumulation of senile plaques, a 
common attribute of this disease (Lin, 2006). Transcription of mitochondrially encoded peptides, 
such as the ND6 and ND2 genes on the mitochondrial light and heavy strands respectively, have 
also been shown to be reduced by 50% in the brains of many Alzheimer’s patients suggesting an 
effect on mitochondrial gene transcription (79).  
Evidence also suggests that change in mitochondrial function contribute to the ageing 
process (14). As an organism ages, electron transport chain function declines leading to a 
subsequent increase in the production of reactive oxygen species (71). These changes seem to be 
brought on by the increasing levels of mutations found in the mitochondrial DNA over time as 
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oxidative phosphorylation processes are continuously being employed. The generation of ROS 
inside the cell leads to the activation of the mitochondrial permeability transition pore (mtPTP) 
which in turn increases the likelihood of apoptosis by releasing the contents of the mitochondria 
into the cellular cytosol, including the apoptotic promoting molecule, cytochrome c (77 and 79). 
Cellular ageing results in the decreased activity of mitochondrial encoded proteins such as those 
found in Complex I and Complex IV of the electron transport chain (71). These studies confirm 
the critical importance of the mitochondrial genome in cellular homeostasis. With this 
knowledge, this thesis aims to uncover how a mutant enzyme, IDH, can alter mitochondrial 
transcription and thereby alter this organelle’s function.  
The Warburg Hypothesis 
  In the 1920s, Dr. Otto Warburg hypothesized that cancer is a disease of metabolism and 
can be interpreted as a disease of mitochondrial misregulation (Presner, 2011). Specifically, 
Warburg proposed that in cancer, there is a general shift in how cells acquire nutrients, generate 
energy and regulate their metabolism (Figure 1-4). In the presence of oxygen, most non-
proliferating undifferentiated cells use the mitochondrial tricarboxylic acid (TCA) cycle to 
metabolize glucose into carbon dioxide by oxidative phosphorylation (83). Through multiple 
enzymatic conversions and phosphorylations, glucose is broken down into two molecules of 
pyruvate, a three carbon chain, in the cytoplasm during glycolysis. These pyruvate molecules are 
then shuttled through the mitochondrial membrane and converted to acetyl-coA molecules where 
they undergo oxidation to create adenosine triphosphates. Once inside the matrix of the 
mitochondrion, one molecule of acetyl-coA is metabolized to ultimately produce three molecules 
of NADH, one molecule of FADH2, one molecule of GTP or ATP and two molecules of CO2. 
The CO2 molecules are taken out of the cell and exhaled out of the body. The GTP/ATP  
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Figure 1-4: The Warburg effect. Comparing the difference in energy usage between 
differentiated tissues and proliferative or tumor tissues. The production of lactate is favored over 
oxidative phosphorylation in tumor samples whether in the presence or absence of oxygen. 
Figure adapted from Vander Heiden, 2009. 
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molecule generated can be used as a fuel source and energy producer. The NADH and FADH2 
molecules produced by the TCA cycle help to shuttle electrons through the mitochondrial inner 
membrane to O2 molecules via oxidative phosphorylation. Through OXPHOS, H
+
 ions are 
subsequently pushed into the intermembrane space to create a gradient of charge across the 
membrane. This gradient helps to provide the necessary energy to synthesize ATP from ADP 
and inorganic phosphate using the ATP synthase enzyme, which ultimately leads to the 
production of about 15 molecules of ATP which, when calculated, totals to about 32 molecules 
of ATP generated per molecule of glucose taken up in the diet (55). This vast amount of ATP is 
used as energy in the cell to do work and catabolize necessary materials.  
In an environment where oxygen is in short supply, such as during strenuous exercise, 
mammalian cells will undergo glycolysis for quick ATP production. This process utilizes a 
glucose molecule to produce two molecules of pyruvate which are then reduced into a total of 
two molecules of lactate. Lactate can be used within the cell to generate two net molecules of 
ATP for energy. This production of ATP through glycolysis is much smaller than the amount of 
energy produced during oxidative phosphorylation and requires much more glucose to produce 
the same effect as the relatively small number of glucose molecules needed during aerobic 
conditions (46). Cancerous cells on the other hand, as observed by Warburg, tend to consume 
extremely large amounts of glucose and produce abnormally high levels of lactate even in the 
presence of ample supplies of oxygen (38). This process, termed aerobic glycolysis, has become 
a defining feature of most cancers of the human body. Today, Otto Warburg’s hypothesis from 
more than 80 years ago has garnered much attention, as aberrant metabolism has evolved as 
another hallmark of cancer biology. In this present work, we aim to uncover how metabolism can 
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be altered by studying the mitochondrial genome and how the effects produced by a mutant 
enzyme can lead to dysregulation in this system. 
The Study of Epigenetics as it Pertains to the Mitochondria 
Early studies uncovered the existence of 5-methylcytosine residues in the human 
mitochondrial genome as well as in many other species including rat, hamster, mouse and cow. 
However, this idea of mitochondrial epigenetics has remained somewhat controversial over the 
past few years. Earlier reports point to the fact that mitochondrial DNA contains no histones and 
instead bundles its content into nucleoids tethered to the mitochondrial inner membrane by the 
protein TFAM (Transcription Factor A) along with other proteins necessary in mitochondrial 
maintenance (22). Also, there was no evidence to suggest that methylases can enter the 
mitochondria in mammals. The Taylor lab has addressed these problems and put this debate to 
rest once and for all. Recent evidence suggests that earlier assessments of the possibility of 
mitochondrial epigenetics may have been incorrect. DNMT1 has been shown to be able to enter 
the mitochondrial genome using an upstream start site in translation that encodes an N-terminal 
mitochondrial leader sequence, allowing mtDNMT1 to enter the mitochondria and methylate 
cytosine residues in the mitochondrial genome (68). The two de novo methyltransferases, 
DNMT3a (11) and DNMT3b (6), have also been suggested to enter the mitochondria, although 
this evidence is not as strong. While not much is known about this new mitochondrial DNA 
modification or its function, evidence has found that 5-methylcytosine preferentially exists at 
non-CpG dinucleotide sites as opposed to CpG dinucleotides which are more commonly found in 
nuclear DNA methylation patterns (Belizzi, 2013). The Taylor lab was also able to uncover the 
existence of 5-hydroxymethylcytosine residues in the mitochondrial genome; while the presence 
of this modification in the mitochondrial genome remains to be determined, levels in mouse  
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Figure 1-5: p53 status affects mitochondrial gene expression in a gene-specific manner. p53 
affects expression level of the mitochondrial isoform of DNMT1 which can lead to an effect on 
gene expression of the protein-coding genes of the mitochondria. Levels of mRNA for ND1 and 
ND6  were differentially expressed after loss of p53. Adapted from Shock, 2011. 
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brain mitochondria have been implicated in the aging process (18). Also of note, cytosine 
modifications in the mitochondrial genome have a gene-specific effect on the protein-coding 
genes as ND6 (the protein encoded on the light strand) is downregulated while ND1 (the first 
protein-coding gene after the ribosomal RNA genes) is upregulated in p53-null cells which 
transcribe an abundance of mtDNMT1 mRNA (Figure 1-5 adapted from 68).With this finding, 
research has been performed to determine that the TET enzymes, as well as DNMTs, can cross 
into the mitochondria and perform their enzymatic functions on mtDNA (6). It stands to reason 
that while not much is known about mitochondrial epigenetics, mitochondrial methylation and its 
subsequent hydroxymethylation may have a serious effect on oxidative phosphorylation and 
energy production in the cell through their effects on gene transcription of the mitochondrial 
genome.  
As mitochondrial dysfunction and metabolic reprogramming seem to play an important 
role in many disease states including cancer, it seems logical that mutant IDH protein would 
have a significant effect on mitochondrial epigenetic levels. Previous studies have identified the 
effect IDH mutation has on nuclear epigenetics as well as histone modifications to control gene 
expression and cellular differentiation respectively, but studies on a possible mitochondrial effect 
have been lacking at this time. We propose that IDH mutation would affect the levels 5-
hydroxymethylcytosine residues found in the mitochondrial genome via production of 2- 
hydroxyglutarate which will lead to the inhibition of TET enzymes located within the 
mitochondria. A fall in 5-hydroxymethylcytosine content could lead to the establishment of a 
hypermethylator phenotype in the mitochondria as previously shown in the nuclear genome. To 
determine if any effects on mitochondrial epigenetics result when IDH mutations are introduced, 
an innovative technique, Methylated DNA Immunoprecipitation (MeDIP), will be used to 
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quantitate the 5mC and 5hmC residues found in the mitochondrial genome, as traditional 
Bisulfite sequencing cannot distinguish between these two modified bases (29). Quantitative 
polymerase chain reaction will be used to quantitatively determine how the levels of 5mC and 
5hmC are affected in the mitochondrial genome, specifically the regions encoding the 12S and 
16S rRNA genes. 
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Chapter 2: Materials and Methods 
Cells, Cell culture, and plasmids used to determine the effect of IDH mutations on 
mitochondria 
  The cDNAs encoding IDH1, IDH2, L2HGDH or D2HGDH were obtained from the 
Arizona State University DNA repository and recloned into either pDEST26 C-FLAG (IDH) or 
pcDNA 6.2/myc (HGDH). Site directed mutagenesis was carried out using the Quick-Change 
Mutagenesis kit from Agilent to generate the IDH1 R132H and IDH2 R172K mutations. All 
cloning and mutagenesis was carried out by the Biological Macromolecule Core Laboratory at 
Virginia Commonwealth University. All plasmids were verified by DNA sequence analysis. 
Both HEK293 and HCT-116 cell lines were used in this project. Cells were grown in either 6-
well plates (for protein extracts) or 100mm dishes (for DNA purification) in DMEM media with 
10% Fetal Bovine Serum (Atlanta) in 10% CO2 in a humidified incubator at 37⁰C.  
Transient transfection 
Once cells reached 70-80% confluency in their respective dishes, transient transfections 
were performed. Plasmids encoding epitope-tagged proteins are shown in Table 1. For 6-well 
plates, 2µg of each plasmid was diluted with 50uL of serum free DMEM media (high glucose) 
and 6µL Polyjet Transfection reagent (SignaGen Laboratories Cat #SL100688) was also diluted 
with 50µL serum free DMEM and added to diluted plasmid. After 15 minutes at room 
temperature, each transfection mixture was pipetted into a well containing 70-80% confluent 
cells. The cells were incubated overnight and the next day fed with DMEM media containing 
10% FBS and 1% Penicillin-Streptomycin. Media was replaced 24 hours post-transfection and, 
after 48 hours, cells were harvested. Cells were washed twice with cold non-sterile PBS  
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Table 1: Table of expression plasmids used in this thesis. Antibobies needed for 
immunoblotting as well as antibiotics necessary for generation of stables is provided.  
Sample Plasmid 1 Plasmid 2 
Western Blot Antibody 
Needed Drug Selection for Stables 
1 IDH1 wild-type   FLAG Neomycin 
2 IDH1 wild-type L2HGDH FLAG/Myc Neomycin/Blasticidin 
3 IDH1 wild-type D2HGDH FLAG/Myc Neomycin/Blasticidin 
4 IDH1 mutant   FLAG Neomycin 
5 IDH1 mutant L2HGDH FLAG/Myc Neomycin/Blasticidin 
6 IDH1 mutant D2HGDH FLAG/Myc Neomycin/Blasticidin 
7 IDH2 wild-type   FLAG Neomycin 
8 IDH2 wild-type L2HGDH FLAG/Myc Neomycin/Blasticidin 
9 IDH2 wild-type D2HGDH FLAG/Myc Neomycin/Blasticidin 
10 IDH2 mutant   FLAG Neomycin 
11 IDH2 mutant L2HGDH FLAG/Myc Neomycin/Blasticidin 
12 IDH2 mutant D2HGDH FLAG/Myc Neomycin/Blasticidin 
13 L2HGDH   Myc Blasticidin 
14 D2HGDH   Myc Blasticidin 
15 pIRES neo2     Neomycin 
16 
pcDNA3.1 
myc/hisB     Blasticidin 
17 Untransfected       
18 pMAX GFP       
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(pH 7.4), scraped from dish and collected by centrifugation in pre-weighed 1.5mL centrifuge 
tubes. Media was removed and cold non-sterile PBS (pH 7.4) was used to wash each well twice. 
Cells were resuspended in 5µL/mg wet weight in SDS lysis buffer (2.25 mL EDTA free protease 
inhibitor tablets (Roche) resuspended in 2X sample buffer (62.5 mM Tris-HCl, pH 7.5, 5% 
glycerol, 2% SDS), 2.025mL water, 225 µL β-Mercaptoethanol) and sonicated on high power 
for 7.5 minutes at 30 seconds on, 30 seconds off intervals in a Diagenode Bioruptor bath 
sonicator and stored at -80⁰C for use in immunoblotting.  
Samples for DNA extraction were transfected in 100mm dishes using 8µg of each 
plasmid, 20µL of Polyjet Transfection reagent and 150µL of serum free DMEM as diluents as 
described above for 6-well plates. After 15 minutes at room temperature, each transfection 
mixture was pipetted onto a plate containing 70-80% confluent cells. As previously described, 
media was replaced 24 hours post-transfection and at 48 hours post-transfection, cells were 
scraped into 1.5mL centrifuge tubes, pelleted and stored at -80⁰C for later DNA extraction.  
Selection of Stable Transfectants 
 To create cell lines that stably express the plasmids of interest, either 100mm 
(Blasticidin resistance plasmids) or 150mm dishes (Neomycin resistance plasmids) were used. 
Cells were brought to 70-80% confluence and transfections were performed as described for 
transient transfections, above. For 150mm dishes, 300uL of serum free DMEM media, 12ug of 
each plasmid DNA and 30uL of polyjet reagent were used. Stable integration of plasmid was 
selected using neomycin (1mg/mL), blasticidin (2µg/mL) or both drugs together, as indicated in 
Table 1. An untransfected control was also used to ensure that plasmids were integrated into the 
cellular genome. Once colonies began to form on the dishes, 12 were removed using sterile 
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polyester Q-tips and placed in one well of a 12-well plate. Media was replaced with designated 
drug until colonies reached confluency in their wells. The cells were then trypsinized from their 
wells, pelleted and aliquoted into 100mm dishes (DNA isolation), 60mm dishes (protein 
extraction and immunoblot) or individual wells of a 24 well plate for cryopreservation, using 
freezing media (90% FBS, 10% DMSO). 300µL of total cells were plated for freezing, while 1/3 
total volume of cells were aliquoted into 60mm dishes and the remaining cells were aliquoted 
into 100mm dishes. 
Protein Concentration Assays 
The Bradford Assay was used to determine protein concentration of each sample that was 
harvested from either 6-well plates (transient transfection) or 60mm dishes (stable transfection). 
Duplicate assays were conducted for each sample as well as for the standard curve. Standard 
curve samples contained 699-799µL of H2O at 20µL intervals, 1µL of SDS lysis buffer and BSA 
(0-10µg) while sample tubes contained 799µL of H2O and 1µL of protein extract. 200µL of 
BioRad dye concentrate (Cat # 500-0006) was added to each tube. After a 15 minute incubation 
at room temperature, absorbance was determined using a spectrophotometer at 595nm 
wavelength. 
Immunoblot Assays of Protein Expression 
 Each sample (40µg) was mixed with an equal volume of Laemmli Sample Buffer 
(475uL Laemmli Buffer (Cat# 161-0737)/25uL of β-mercaptoethanol), and total volume was 
adjusted to 37µL with SDS lysis buffer. Samples were run alongside Precision plus Dual Color 
protein ladder (Biorad Cat# 1610374) in 1X Running Buffer (25mM Tris, 250mM glycine, 0.1%  
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Table 2: List of antibodies used for western blotting  
Antigen 
Primary Ab 
obtained 
from 
Primary 
Ab 
Dilution 
Blocking 
Buffer 
Secondary 
Ab Used 
Secondary 
Ab 
Dilution 
Expected 
protein 
band 
size 
Chemiluminescent 
substrate prepared 
FLAG 
Sigma 
Aldrich 
Cat. F1804 
1:500 
Starting 
Block 
Goat 
Anti-
Mouse 
1:15000 50 kD ½ Dura 
Myc 
Invitrogen 
Cat. R950-
25 
1:2000 
Starting 
Block 
Goat 
Anti-
Rabbit 
1:10000 50 kD Full Pico 
IDH 
Cell 
Signaling 
Cat. 12652 
1:1000 
Starting 
Block 
Goat 
Anti-
Rabbit 
1:1000 50 kD ¼ Dura  
VDAC 
Cell 
Signaling 
Technology 
Cat. 4661 
1:2500 
Starting 
Block 
Goat 
Anti-
Rabbit 
1:3000 32 kD Full Pico 
Cyclophilin A 
Millipore 
Cat. 07-313 
1:5000 
Starting 
Block 
Goat 
Anti-
Rabbit 
1:5000 18 kD Full Pico 
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SDS). Samples were boiled for 10minutes. Proteins were resolved on a 10% polyacrylamide gel 
for one hour at 150 volts. Gel was washed in water then transferred to a PVDF membrane 
(Millipore, Cat# IPVH0010) that was pre-washed in 100% Methanol. Transfer was performed in 
ice bath with stir bar placed in transfer apparatus for 50 minutes at 100 volts in 1X Transfer 
Buffer (25mM Tris-HCl, pH 8.3, 192mM glycine, 10% Methanol and 0.04% SDS), and 
membranes were incubated in Starting Block buffer (Thermo Scientific) overnight at 4
o
C. 
Membranes were washed in 1X TBS-T (25mM Tris-HCl, pH 8.3, 192mM glycine, 0.04% SDS, 
0.1% Tween-20) for 5 minutes and exposed to epitope-specific primary antibodies for one hour. 
All primary and secondary antibodies, as well as dilutions used, are listed in Table 2. VDAC or 
Cyclophilin A was used as a loading control. After one hour incubation, membranes were 
washed in 1X TBS-T thrice for 5 minutes and then incubated with secondary antibody for one 
hour (using antibodies specific for Fc regions of primary antibodies). After incubation, three 10 
minute washes in 1X TBS-T were performed. During this time, chemiluminescent substrates 
were prepared using either West Dura (Pierce, Cat# 34075) or West Pico (Pierce, Cat# 34080). 
Once washed, membranes were dried, incubated in substrates for 3 minutes, wrapped in saran 
wrap and exposed on film to determine protein expression levels.  
Purification of DNA from transfected cell lines  
Once protein expression levels had been determined, cell pellets from 100mm dishes for 
DNA extraction were lysed using the DNeasy Blood and Tissue Kit from Qiagen (Cat# 69504), 
following the manufacturer’s protocol. An RNase treatment was used to ensure pure DNA was 
collected and any RNA was destroyed in each sample, since RNA can also be modified at 
cytosine residues. The DNA was further purified to destroy any remaining RNA by incubating 
with 0.5M NaOH at 37⁰C overnight in a water bath. DNA was recovered following phenol-
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chloroform extraction by ethanol precipitation. Extracted DNA was resuspended in 200uL of AE 
buffer (Qiagen) and concentration was measured on the NanoDrop spectrophotometer to 
determine DNA concentration. With this purified DNA, samples were sonicated twice at high 
power for 15 minutes using intervals of 30 seconds on, 30 seconds off to obtain DNA fragments 
between 200-700bp. This sonicated DNA was resolved on a 1.5% agarose gel for 70 minutes at 
100 volts to verify the correct fragment size of DNA needed for MeDIP experiments.  
MeDIP/Hydroxy-MeDIP Assay 
Once DNA of correct length and purity was obtained, MeDIP was performed to obtain 
methylated and hydroxymethylated DNA of sample (visual of MeDIP displayed in Figure 2-1). 
As the 5-methylcytosine and 5-hydroxymethylcytosine antibodies were produced in mouse and 
rabbit species respectively, both an IgG mouse and IgG rabbit antibody were necessary as 
measures of baseline in this experiment. 4ug of purified and sonicated DNA was brought up in 
Tris EDTA buffer (10mM Tris, 1mM EDTA) to 450uL total volume. This procedure was 
repeated to generate 4 tubes of 4µg for each DNA sample used in MeDIP experiment. These 
tubes were subjected to denaturation by submerging in boiling water for 10 minutes and then 
immediately placed on ice for 10 minutes. After denaturation, samples were mixed with 51uL of 
10X IP buffer (100mM Na-Phosphate pH 7.0, 1.4M NaCl, 0.5% Triton X-100) and rotated end-
over-end at 4⁰C overnight with 2µg of one specific antibody for each tube which include: IgG 
rabbit monoclonal control (Santa Cruz Biotechnologies, Cat# SC-2027), IgG mouse polyclonal 
control (Millipore, Cat# 12-371),  5-methylcytidine antibody (Epigenetek, Cat# A-1014) or 5-
hydroxymethylcytidine antibody (Active Motif, Cat# 39769). To ensure proper capture of 5-
methyl and 5-hydroxymethyl residues, IgG protein beads were pre-blocked prior to use in 
immunoprecipitation the following day. Beads were washed three times in 0.1% PBS-BSA 
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Figure 2-1: Schematic representing the protocol used for the MeDIP/Hydroxy-MeDIP 
method. Protocol followed to ensure adequate isolation of methylated/hydroxymethylated DNA 
residues respectively.  
 
 
 
29 
 
 (10mg of BSA were dissolved in 9mL of 1X PBS pH7.4 and 1mL of H2O), each time being 
rotated end-over-end at 4⁰C for 5 minutes and pelleted at 4500rpm for 5 minutes at 4⁰C. These 
beads were resuspended in an equivalent volume of 1X IP buffer and blocked using 5µg/30µL 
IgG bead slurry BSA and 5µg/30µL IgG bead slurry sonicated Lambda DNA. Beads were 
rotated at 4⁰C for three hour incubation. Afterwards, beads were washed three more times with 
0.1% PBS-BSA, rotated and pelleted as before. 50% IgG bead-1X IP slurry was prepared again 
and 20µL of slurry was aliquoted into each sample to capture antibodies that adhered to DNA 
regions of interest and rotated with beads for 2 hours at 4⁰C. After incubation, beads were 
pelleted and supernatants of IgG control samples were saved for later use as input samples for 
quantitative PCR. Beads of all samples were then washed with 500µL 1X IP solution, rotated 
end-over-end for 10 minutes and pelleted at 4500rpm for 2 minutes at 4⁰C three times. After 
pelleting beads for the third time, samples were resuspended in 250µL Proteinase K digestion 
buffer (50mM Tris pH 8.0, 10mM EDTA, 0.5% SDS) and 3.5µL of Proteinase K (20mg/mL) 
was added to each sample and tubes were left to incubate for 3 hours at 50⁰C in a rotating water 
bath. Samples, including saved supernatants from IgG controls, were then extracted with of 
25:24:1 phenol:chloroform:isoamyl alcohol (250µL), spun at 13200rpm for 5 minutes at 4⁰C and  
the aqueous layer containing DNA was removed.  Samples were then extracted with and an 
equivalent volume of chloroform (250µL), and spun again at 13200rpm for 5 minutes at 4⁰C. 
The top aqueous layer was collected and precipitated with 1/10
th
 the volume of 3M sodium 
acetate (25µL), glycogen (4µL) and 100% ethanol (750µL) to recover immunoprecipitated DNA. 
Samples were left to precipitate overnight at -80⁰C. The following day, samples were spun at 
13200rpm for 20 minutes at 4⁰C to pellet DNA. Supernatant was removed and 70% Ethanol 
(500µL) was dispensed into each sample and spun again at 13200rpm for 10 minutes at 4⁰C. 
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Supernatant was removed from pelleted DNA and samples were dried for 10 minutes, 
resuspended in 75µL TE buffer and stored at -20⁰C for later use.  For the experiment using 
HCT116 cells, the supernatants of each IgG control were not collected and the material that 
bound to the beads in the IgG mouse or IgG rabbit samples was used as a baseline to compare to 
their respective 5-methylcytosine or 5-hydroxymethylcytosine antibodies. This experiment was 
presented as a measure of the fold change difference between the IgG controls and their 
respective 5mC and 5hmC counterparts using the following equation: 
Fold Change = 2
-ΔΔC(t) 
 
where ΔΔC(t) is the value obtained by subtracting the IgG cycle threshold values from the 
experimental (5mC or 5hmC) cycle threshold value after normalization to the H2O blank cycle 
threshold values. For experiments involving HEK293 cells, supernatants from 
immunoprecipitated IgG controls were collected and used to quantify amount of input DNA 
using qPCR. 
Assessment of DNA-IPs  
Endpoint PCR was performed to determine a visual difference between both 5mC and 
5OH and their IgG controls. Primers used were for both the 12S and 16S regions of the 
mitochondrial genome:  
12S-Forward: 5′-AGTTCACCCTCTAAATCACCACG-3′                                                       
12S-Reverse: 5′-TGACTTGGGTTAATCGTGTGACC-3′                                                               
16S-Forward: 5′-ACCTTACTACCAGACAACCTTAGCC-3′                                                  
16S-Reverse: 5′-TAGCTGTTCTTAGGTAGCTCGTCTGG-3′ 
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12S and 16S master mixes were produced using 12.5µL of HotStart Taq DNA polymerase, 1µL 
of 10µM forward and reverse primers and 8.5µL H2O per tube. 24µL of Master Mix, along with 
1µL of sample DNA was placed into clear microfuge tubes while PCR was run at 35 cycles 
under the following cycling conditions: 
1. 950C for 15 minutes 
2. 940C for 30 seconds 
3. 550C for 30 seconds 
4. 720C for 30 seconds 
5. Go to Step 2 35 times 
6. 720C for 5 minutes 
7. 40C forever 
 H2O blank as well as input DNA from the supernatant collected during the MeDIP protocol was 
used as both a negative and positive control respectively. PCR amplified products were then 
resolved on a 1% agarose gel for 70 minutes at 100 volts.  
Quantitative PCR measurement of mtDNA in DNA-IP samples 
 Quantitative PCR was carried out using the same primers and cycling conditions used for 
Endpoint PCR. Samples were amplified over 35 cycles using Quantitect Sybr Green Dye 
HotStart Taq mastermix from Qiagen. The following cycling conditions were used: A no 
template control was run to detect any background amplification, while a standard curve was 
produced using 10-fold serial dilutions to 1:1000 of the wild-type IDH1 IgG mouse control 
sample following IP. Both IgGM and IgGR inputs were diluted 1:100 while samples treated with 
the 5OH antibody were diluted 1:5. Dilution factors for each treatment of each sample were 
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measured using the Opticon software and this data was expressed as a percentage of the input. 
Furthermore, data was normalized to IDH 1 or IDH2 wild-type to determine the difference in 
abundance of each epigenetic modification. 
Treatment with Octyl-(D)-2-hydroxyglutarate  
 HEK293 cells were plated in 100mm dishes at 30-40% confluency and fed using 10% 
FBS DMEM. Cells were left to incubate overnight in 10% CO2 incubator at 37⁰C. The following 
day, cells were treated with either 1µL or 10µL of 10mM stock solution of octyl-(D)-2-
hydroxyglutarate (Toronto Research Chemicals Inc.) in DMSO to bring concentrations to 1µM 
or 10µM respectively. A no-drug control was used in this experiment as well as a DMSO vector 
control. Drug was left on plates for 48 hours and media was not removed. Cells were scraped 
from dish after 48 hours and pelleted for DNA isolation. The DNeasy Blood and Tissue Kit from 
Qiagen was used as previously described and samples were sonicated twice at high power for 15 
minutes using intervals of 30 seconds on, 30 seconds off to obtain fragments of DNA between 
200 and 500 base pairs. Sonicated samples were resolved on a 1% agarose gel for 70 minutes at 
100 volts. MeDIP technique was followed as described above to isolate 5-methyl and 5-
hydroxymethyl residues found in cells. 12S and 16S rRNA regions of the mitochondrial genome 
were amplified using both Endpoint and qPCR as described to determine the effect of this cell 
permeable analog of 2-hydroxyglutarate on the mitochondrial epigenome. Conditions for PCR 
were followed as described above.  
 Treatment with an IDH1 R132H Mutation Inhibitor, AGI5198 
HEK293 cells that stably express the IDH1 R132H mutation were plated in 100mm 
dishes at 30-40% confluency and fed using 10% FBS DMEM. Cells were left to incubate 
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overnight in 10% CO2 incubator at 37⁰C. The following day, cells were treated with 5µL of 
10mM stock solution of AGI-5198 drug, a known IDH1 R132H mutation inhibitor, bringing the 
concentration of drug to 5µM. This stock solution was initially resuspended in DMSO. Both a 
no-drug treated and DMSO control was used for this experiment. After drug treatment, cells 
were harvested 48 and 144 hours later. Media was replaced 72 hours after initial treatment for 
144 hours treated cell. Cells were scraped and pelleted for DNA isolation using the Qiagen 
Tissue and Blood kit as previously described. Samples were sonicated and subjected to MeDIP 
protocol as detailed above. To determine if this inhibitor drug had any effect on the 
mitochondrial epigenome, the 12S and 16S primer pairs (listed above) were amplified using both 
Endpoint and qPCR for a visual as well as quantitative determination.   
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Chapter 3: Results 
The effect of IDH mutations on mitochondrial epigenetics using the HCT-116 cell line 
 Preliminary studies were performed using HCT116 cells to determine if the IDH1 R132H 
or IDH2 R172K mutations affect the levels of 5-methylcytosine and 5-hydroxymethylcytosine 
found within the mitochondrial genome of this cell line. These studies were originally begun in 
the summer of 2012 by Hannah Gardner. HCT-116 cells were used in these studies because they 
have an abundance of mitochondria within each cell. Cells were transfected with the plasmids 
shown in Table 1 to determine how either the cytoplasmic (IDH1) or mitochondrial (IDH2) 
isoforms of IDH would affect the epigenome of the mitochondria. Co-transfection of IDH mutant 
samples with the (D)-isoform of 2-HGDH was also carried out to determine whether changes in 
the level of 5-hydroxymethylcytosine resulting from effects of mutant IDH could be rescued, 
since this enzyme, under normal conditions, converts 2-hydroxyglutarate to α-ketoglutarate to 
keep the levels of 2-HGlow within the cell. The 2-HGDH enzyme should therefore relieve the 
competitive inhibition of the TET enzymes by 2-HG. A GFP control was used to visualize the 
efficiency of transfection in this cell line.  
Cells transfected with GFP were viewed under a fluorescence microscope 24 and 48 
hours post transfection as a measure of transfection efficiency (Figure 3-1). After 24 post 
transfection, 30-40% of cells glowed green under the microscope. 48 hours post-transfection, 
approximately 75% of cells glowed green under the fluorescent microscope indicating the level 
of transfection efficiency. After 48 hours, transfected cells were harvested for protein expression 
analysis from the transfected plasmids. Once the protein concentration of each sample was 
determined, immunoblotting was performed to determine protein expression level of each  
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Figure 3-1: Determining transfection efficiency in HCT-116 cell line. Microscopy images of 
GFP transfected HCT-116 cells 24 hours (A) and 48 hours (B) after initial transfection to 
determine efficacy of transient transfection 
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Figure 3-2: Analysis of protein expression levels of transiently transfected HCT-116 cells 
using immunoblotting. IDH proteins were analyzed using a FLAG-specific antibody while 
2HGDH proteins were analyzed using a Myc antibody. VDAC was used as a loading control. 
These immunoblots were performed by Hannah Gardner.  
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sample. FLAG-tagged IDH samples were examined using an antibody specific to the FLAG tag 
located  at the C-terminus of each IDH protein. A MYC antibody was used to visualize the 
MYC-tagged 2-hydroxyglutarate dehydrogenase plasmids that were co-transfected into the 
appropriate samples. A VDAC antibody was used to ensure equivalent loading of each sample 
onto the gel as it is a common ion channel found on the surface of the outer mitochondrial 
membrane. As can be seen in Figure 3-2, each sample expressed the appropriate IDH plasmid 
while co-transfected samples expressed both FLAG-tagged IDH as well as the MYC-tagged (D)-
2HGDH plasmid. Samples transfected with the L-isoform of 2HGDH did not appear to express 
the epitope tag encoded on its plasmid, although DNA sequence analysis verified the correct in-
frame cloning of this cDNA.  
 After expression levels were confirmed, the cells pelleted for DNA extraction were 
thawed and total cellular DNA, which includes mitochondrial DNA, was isolated from each 
sample. These samples were sonicated, to shear the DNA to a length of 200-500 base pairs to 
avoid amplifying modified DNA outside the regions of interest. The appropriate sonication of 
each sample was confirmed using a 1% agarose gel stained with Ethidium Bromide. Once the 
proper length of DNA was obtained for each sample, MeDIP was performed as detailed in the 
methods section. After MeDIP, endpoint PCR was utilized at 35 cycles to obtain a visual 
representation of how much modified DNA was present in each sample compared to its specific 
IgG control (Figure 3-3). The signal for the 5-hydroxymethylcytosine residues found in the 12S 
and 16S regions of the mitochondrial genome is very robust and well above its respective IgG 
Rabbit control antibody which is interpreted as a measure of assay background. In contrast, the 
5-methylcytosine signal is low and frequently cannot be distinguished from its IgG Mouse 
control using endpoint PCR. 
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To obtain a quantitative difference between IDH wild-type and IDH mutant samples, 
qPCR was performed. Amplification of the 12S rRNA region of the mitochondrial genome 
(Figure 3-4), indicates that the introduction of the IDH1 R132H mutation results in a dramatic 
decrease in the level of 5hmC residues, about 4.5 fold relative to the levels of 5hmC in the IDH1 
wild-type transfected sample. A slight increase in the abundance of 5mC residues relative to that 
found in the IDH1 wild-type sample is found in the mitochondrial genome when the IDH1 
R132H mutation is expressed in this HCT116 cell line. However, the signal obtained from the 5-
methylcytosine specific antibody is low, suggesting a low level of 5-methylcytosine residues in 
the mitochondrial genome. Background signal obtained with the mouse IgG control antibody is 
often as high as the 5mC antibody signal. Previous studies in the lab have shown substantial lot-
to-lot variation in the background signal with mouse IgG. Multiple IgG mouse control antibodies 
will be tested in future experiments to more accurately determine the level of 5-methylcytosine 
modification found in the mitochondrial genome. However, since the level of 5-
hydroxymethylcytosine found in these samples is well above baseline IgG control levels, it is 
reasonable to conclude that there is a preponderance of 5hmC modified DNA in the 
mitochondrial genome although the function of this modification in the mitochondria remains to 
be determined. When analyzing the level of 5hmC modified DNA in the 16S rRNA region after 
the incorporation of the IDH1 mutation, a similar trend is found as that seen in the 12S rRNA 
region (Figure 3-5). Once again, a 4.5 fold decrease in 5hmC signal is observed when mutant 
IDH1 is expressed compared to the IDH1 wild-type sample, indicating a substantial reduction in 
the amount of 5hmC in the 16S rRNA region of the mitochondrial genome. When analyzing the 
5mC content present in the 16S rRNA region, we observed that the levels of 5mC increase in 
IDH1 mutated HCT-116 cells compared to the wild-type sample. However, once again, the 
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abundance of 5mC residues found in the 16S rRNA region of the mitochondrial DNA does not 
rise above the baseline IgG mouse control levels indicating a problem with this lot of IgG control 
antibody as previously mentioned. 
 Results obtained with transfection of the IDH2 R172K mutation, were somewhat 
different to those seen with the IDH1 R132H mutation. In IDH2 mutant transfected HCT116 
cells, the levels of both 5mC and 5hmC are reduced when compared to their IDH2 wild-type 
counterparts. These results were similar in both the 12S (Figure 3-4) and 16S (Figure 3-5) 
regions of the mitochondrial genome. In the 12S rRNA region, there is a clear 4-fold drop in the 
levels of both 5hmC and 5mC. Examination of the 16S rRNA region indicates a more modest 2-
fold decrease in 5hmC level when comparing IDH2 wild-type to IDH2 mutant while the amount 
of 5mC modified DNA present in this region is nearly 90% less in the IDH2 mutant sample 
compared to wild-type. Fortunately, the level of 5mC in both the ribosomal genes is above 
baseline (IgG control) in the IDH2 wild-type transfected cells however, the level falls below 
baseline with the introduction of the IDH2 mutation. The levels of 5mC and 5hmC were 
measured in the samples that were co-transfected with the D2 isoform of 2-HGDH as well since 
the (D)-isoform of 2-hydroxyglutarate is solely produced by these IDH mutations. With the 
introduction of this enzyme, the levels of 5hmC and 5mC begin to rise towards levels similar to 
those found in the IDH2 wild-type sample. In the 12S rRNA gene region, 5hmC and 5mC levels 
rise by 50% and 150% respectively compared to the IDH2 mutated samples. Since 2-HGDH 
functions to convert 2-HG to α-ketoglutarate, the effect of this enzyme was expected to reverse 
the decrease in 5hmC levels caused by mutant IDH through relief of  competitive inhibition of 
the TET enzymes by 2-HG. The increase in 5mC levels in this co-transfected sample was 
opposite to that expected and likely reflects the very high IgG control in the mutant IDH samples  
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12S
16S
 
Figure 3-3: Example of endpoint PCR of HCT116 cells after transient transfection of IDH1 
wild-type plasmid. DNA that was not used for MeDIP protocol was used for Input control. Both 
the 12S and 16S regions of the mitochondrial genome were analyzed using specific primers. 
PCR produce (200bp) was resolved on a 1% agarose gel. IgG Mouse compares to 5-
methylcytosine while IgG Rabbit is compared to the signal produced by the 5-
hydroxymethylcytosine antibody. 
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Figure 3-4: Expression of mutant IDH causes a reduction in the level of 5hmC in the 12S 
gene of the mitochondrial genome. Shown is a graphical representation of the effects of IDH 
enzymes on the abundance of 5-methylcytosine and 5-hydroxymethylcytosine in the 12S rRNA 
region of the mitochondrial genome. Samples were normalized to their respective IgG controls. 
Both IDH1 (A) and IDH2 (B) are displayed.  
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
5mC 5OH 
Fo
ld
 C
h
an
ge
 r
e
la
ti
ve
 t
o
 Ig
G
 c
o
n
tr
o
ls
 
Antibody 
IDH1wt 
IDH1mutant 
IgG 
0 
1 
2 
3 
4 
5 
6 
7 
8 
5mC 5OH 
Fo
ld
 C
h
an
ge
 r
e
la
ti
ve
 t
o
 Ig
G
 c
o
n
tr
o
ls
 
Antibody 
IDH2wt 
IDH2mutant 
IDH2mutant/D2 
IgG 
42 
 
A 
 
B 
 
Figure 3-5: Expression of mutant IDH causes a reduction in the level of 5hmC in the 16S 
gene of the mitochondrial genome. Shown is a graphical representation of the effects of IDH 
enzymes on the abundance of 5-methylcytosine and 5-hydroxymethylcytosine in the 16S 
ribosomal RNA region of the mitochondrial genome. Samples were normalized to their 
respective IgG controls. Both IDH1 (A) and IDH2 (B) are displayed. 
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(Figures 3-4 and 3-5). However, a possible novel interaction between 2-HGDH and the 
methylation machinery of the mitochondria cannot be ruled out at this time. Further experiments 
will need to be performed to understand which of these two possibilities is at play. Interestingly, 
when analyzing the 16S rRNA gene cotransfection with IDH mutant and (D)-2HGDH, the level 
of 5mC increases by nearly 2-fold when compared to the level of 5mC found in the IDH2 
mutated sample while the 5hmC level decreases by about 0.5 fold compared to IDH2 mutant 
levels. This result is different from thatfound in the nuclear genome and the 12S rRNA region, 
pointing to a possibly different mechanism of action for cytosine modification between these two 
ribosomal RNA regions of the mitochondrial genome.  
The effect of IDH mutations on mitochondrial epigenetics using the HEK293 cell line 
 HEK293 cells were used to validate whether the effects of IDH mutations on 
mitochondrial epigenetics, observed using the HCT116 human cancer cell line, could be 
replicated in another cell line. The embryonic kidney cell line has been used by several other labs 
to uncover the role of IDH mutation on nuclear epigenetics and is much less mutated than the 
HCT-116 cell line. Using either wild-type or mutant IDH containing plasmids as well as co-
transfections using the different 2HGDH isoforms (Table 1), transient transfection was 
performed once cells reached 70-80% confluency on their respective plates as previously 
described. Photomicrographs of the GFP plate were taken 24 hours and 48 hours after 
transfection to determine the efficiency of the transfection. As shown in Figure 3-6, about 50% 
of the cells fluoresce under the microscope after 24 hours post-transfection and about 90% of the 
cells fluoresce 48 hours after transfection. After protein concentrations were determined, 
immunoblotting was carried out as described using a VDAC loading control to assess equivalent 
loading of each of the samples onto the blot. Each of the IDH samples (samples 1-12)  
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Figure 3-6: Determination of Transfection Efficiency of HEK293 cells. Microscopy image of 
GFP-expressing HEK293 cells 24 hours (A) and 48 hours (B) after initial transient transfection. 
These images were used as rough estimates of transfection efficiency.  
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FLAG
Myc
VDAC
Figure 3-7: Immunoblots of transient transfection using HEK293 cell line. IDH proteins 
were analyzed using a FLAG-specific antibody while 2HGDH proteins were analyzed using a 
Myc antibody. VDAC was used as a loading control. 
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appropriately express the epitope-tagged protein on the plasmid that was transfected into the 
cells whether they were IDH1 wild-type or mutant or IDH2 wild-type or mutant (Figure 3-7). 
Interestingly, all IDH2 expressing plasmids displayed two bands at 46 and 50 kD. These bands 
represent the different subcellular locations of the protein as 39 amino acids are cleaved from the 
N-terminus upon entry into the mitochondria. The upper band represents the protein before 
mitochondrial localization as not all of the protein had entered this organelle before harvesting of 
the cells for protein extract while the lower band represents IDH2 protein that had entered the 
mitochondria. As before, the epitope tag encoded on the L2HGDH plasmid was not detectable. 
To detect this protein, an antibody directed against the protein itself may be necessary if 
available and alternative or N-terminal tags will be tested. The D2HGDH protein was expressed 
very well. No protein tagged with either FLAG or Myc was expressed in the blots of either the 
vector control or the GFP control used in this experiment indicating proper transfection of all 
samples. After determining that each sample expressed the appropriate proteins, the total cellular 
DNA was isolated. Pure DNA was sonicated to lengths between 200 to 500 base pairs and 
resolved on a 1% agarose gel to ensure that qPCR would detect modified residues only in the 
vicinity of the amplified fragment (Figure 3-8). For these experiments, the supernatant of both 
the IgG Mouse and IgG Rabbit samples were collected and used to determine input in order to 
control for variability in the amount of DNA used in each assay. The 5mC and 5hmC values 
would be measured as a percentage of input when compared to their IgG mouse and IgG rabbit 
controls respectively. Once the MeDIP was performed, endpoint PCR was used to validate the 
success of the IP (Figure 3-9). As can be seen, when amplifying the 12S and 16S rRNA regions 
of the mitochondrial genome, the IgG rabbit control gives a much fainter signal than its 5- 
hydroxymethylcytosine counterpart indicating an abundance of 5hmC in this sample.  
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200 bp
500 bp
 
Figure 3-8: Sonication of purified DNA using HEK293 cells. Samples were sonicated between 
200 to 500 bp to produce small enough DNA fragments useful for MeDIP protocol. Sonicated 
samples were resolved on a 1% agarose gel run for 70 minutes at 100 volts.  
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Figure 3-9: Endpoint PCR of HEK293 cells. Samples shown were transiently transfected with 
IDH1 mutant plasmid. DNA that was not used for MeDIP protocol was used for Input control. 
Both the 12S and 16S regions of the mitochondrial genome were analyzed using specific 
primers. The 200 bp amplicon was resolved on a 1% agarose gel.  
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Unfortunately, the 5mC signal cannot be distinguished from its IgG mouse signal leading one to 
conclude that a difference in abundance of 5mC compared to background cannot be determined 
using the endpoint PCR method. It is possible that there is a much smaller amount of methylated 
cytosine residues in the mitochondrial genome. To better understand how IDH mutation affects 
the abundance of DNA modifications in the mitochondrial, qPCR was performed to obtain a 
quantitative measurement of whether and how the levels of 5hmC and 5mC areaffected 
following expression of IDH mutations.  
As shown in Figure 3-10, in the 12S rRNA region of the mitochondrial genome, 
enrichment for 5hmC is substantially greater than the IgG rabbit control for each sample with the 
introduction of either IDH1 or IDH2 wild-type plasmids. This 5hmC signal is reduced by 50% or 
greater when IDH is mutated, most likely due to competitive inhibition of the TET enzymes by 
the 2-hydroxyglutarate produced by this enzyme. This effect is similar to that observed in HCT-
116 experiments. The decrease in 5hmC content in HEK293 cells was partially rescued by co-
transfection with the (D)-2-HGDH enzyme, which is expected to convert excess 2-HG to α-
ketoglutarate, thereby partially relieving the inhibition placed on the TET enzymes by 2-HG. 
While restoration of 5hmC levels was observed by expression of the 2-HGDH enzyme, the levels 
did not reach those of the IDH wild-type samples. The amount of 2-HG produced by these 
mutant enzymes is substantial and may be too large for the 2-HGDH enzyme to convert back to 
α-ketoglutarate during the 48 hour time course of this experiment. Since the physiological 
concentration of the 2-HG oncometabolite is very low in cells (0.1nM), the kinetic parameters of 
this enzyme in the face of millimolar concentrations are not yet characterized. It is also important 
to keep in mind that the data presented here represent one of three biological replicates and the 
data for the other replicates are still being analyzed.   
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 The 16S rRNA region, showed similar results to those shown in the 12S rRNA region. 
The wild-type IDH1 5hmC level is high compared to its IgG rabbit control (Figure 3-11), while 
transfection with plasmid expressing mutant IDH1 results in a 50% reduction in the level of 
5hmC in comparison to the IDH wild-type level, indicating loss of 5hmC at the 16S rRNA 
region of the mitochondrial genome. Co-transfection with (D)-2-HGDH partially restores the 
level of 5hmC, likely due to the relief of the inhibition placed on the TET enzymes by 2-HG.  
Surprisingly, for IDH2, the mitochondrial isoform of this enzyme, the levels of 5hmC in the 16S 
region, are very similar between IDH2 mutant and wild-type IDH2-transfection. This trend is 
somewhat different from that observed in the HCT-116 cell line and in nuclear genomic DNA 
once again demonstrating the possibility that these different mitochondrial genes react 
independently of each other to stimuli. Again, it is also important to realize that this is one single 
biological repeat of three so the trend may be specific to this repeat and will need to be analyzed 
along with the other repeats to determine the biological effect of this mutated enzyme. Since the 
concentration of α-ketoglutarate in the mitochondria is much greater than in the cytoplasm, the 
conversion of this metabolite to 2-HG may not be as pronounced when IDH2 is mutated as 
compared to IDH1. Mass spectrometry will be used in future experiments to determine the level 
of 2-HG produced by each mutation.  
The changes in levels of 5-methylcytosine in DNA samples from these transfected HEK 
cells were inverse to those seen in the levels of 5-hydroxymethylcytosine for IDH1 transfections. 
When the IDH1 wild-type plasmid was introduced into HEK293 cells the levels of 5mC were 
below the baseline levels determined by the IgG controls in both the 12s and 16s regions of 
mitochondrial DNA but  the introduction of a IDH1 R132H mutation brought about a rise, above 
baseline, in the levels of methylation found in these ribosomal gene regions. This low signal  
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B. 5mC 
 
Figure 3-10: Analysis of epigenetic modification of the 12S rRNA gene after transfection of 
HEK293 cells with wt and mutant IDH. The abundance of 5-hydroxymethylcytosine (A) and 
5-methylcytosine (B) residues found in the 12S ribosomal RNA region of human mitochondrial 
DNA after transfection of HEK293 cells expressed as % of input DNA.  
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A. 5hmC 
 
B. 5mC 
 
Figure 3-11: Analysis of epigenetic modification of the 16S rRNA gene after transfection of 
HEK293 cells with wt and mutant IDH. The abundance of 5-hydroxymethylcytosine (A) and 
5-methylcytosine (B) residues found in the 16S ribosomal RNA region of human mitochondrial 
DNA after transfection of HEK293 cells, expressed as % of input DNA.  
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makes it difficult to determine the levels of 5mC in the mitochondrial genome when IDH is not 
mutated and thus these samples cannot be adequately compared to each other. It is also difficult 
to establish a trend since the levels of the IgG mouse control antibody differ drastically between 
each sample. This technical issue is currently being resolved in the lab.   
A similar trend exists when IDH2 is mutated in that the percentage of methylated 
cytosine residues rises compared to the levels found in IDH2 wild-type samples. Also of interest 
is that when IDH2 mutant samples were co-transfected with (D)-2-HGDH, the level of 5mC 
decreased which may mean that this enzyme is working to convert excess 2-HG back to α-
ketoglutarate thereby relieving the inhibition placed on the TET enzymes and allowing for more 
hydroxylation of 5-methylcytosine residues. This trend is similar in both the 12S and 16S rRNA 
gene regions. This experiment was repeated in three separate biological repeats using HEK293 
cells however, as previously mentioned, only one repeat is shown in the figures above. This data 
is currently being analyzed further to determine if the trends above are consistent between each 
biological repeat. Also, since the IgG mouse control antibody provides different levels of 
enrichment between samples, it is not possible to accurately determine how IDH mutations affect 
the methylation of cytosine residues in the mitochondria, and we will test different mouse IgG 
samples to obtain material that consistently yields low background values.. 
The effect of Long-Term Expression of IDH mutants 
To determine how IDH mutations affect the mitochondrial epigenome over time, cell 
lines stably expressing the IDH1 wild-type and mutant cDNAs, as well as those expressing IDH2 
wild-type and mutant cDNAs, were created. This experiment was performed to determine if a 
similar hypermethylator phenotype as that produced in the nuclear genome develops in the 
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mitochondria and determine whether these mutant enzymes cause a change in mitochondrial 
gene expression or metabolic function of the mitochondria. This experiment was performed 
using HEK293 cells and cells were transfected and subjected to neomycin selection (1mg/mL) to 
eliminate cells that did not integrate the IDH plasmids into their genomes. As this DNA is 
integrated randomly into the genome and might be present in multiple copies, immunoblotting 
was performed to determine the level of expression of the transgene in each clone. Since these 
integration events are random and can occur multiple times in the genome, many clones were 
isolated for each plasmid and analyzed for protein expression using the FLAG antibody. To 
control for these multiple integration events, master cultures were also created, analyzed for 
protein expression and frozen for later use to determine the overall average effect of these mutant 
IDH proteins. Once confirmed, three clones of each IDH-expressing sample were analyzed to 
determine if the level of this enzyme being expressed was physiologically relevant to the levels 
found in normally untransfected cells. This was done to ensure that changes in the levels of 
5hmC and 5mC were relevant to those found in human tumor samples. The endogenous levels of 
IDH were determined using an antibody specific for IDH2 that was able to recognize both the 
IDH1 and IDH2 isoforms present in the cell. These stable clones were compared to untransfected 
control HEK293 cells to determine the degree of overexpression of each in the stable cell culture. 
VDAC was used as a loading control (Figure 3-12) as well as a Cyclophilin A antibody which 
recognizes a ubiquitously expressed nuclear receptor protein. The Cyclophilin A antibody was 
used for the IDH2 expressing clones (Figure 3-13) since we observed fluctuating levels of 
VDAC signal in these experiments, possibly related to effects on mitochondrial integrity. The 
clones that were chosen (Figure 3-12 & Figure 3-13) expressed their FLAG-tagged IDH 
plasmids. All clones expressed either equivalent or greater amounts of the IDH protein,  
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Figure 3-12: IDH expression levels in IDH1 mutant and wild-type stable clones. Three 
separate wild-type clones as well as three separate IDH1 mutant expressing clones were analyzed 
to determine level of transgene expression. An untransfected control was used to determine 
levels of endogenous IDH expressed in HEK293 cells. VDAC was used as a loading control to 
assess equal loading of each sample.  
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Figure 3-13: IDH expression levels in IDH2 mutant and wild-type stable clones. Three 
separate wild-type and mutant expressing clones were analyzed to determine level of transgene 
expression. An untransfected control was used to determine levels of endogenous IDH expressed 
in HEK293 cells. Cyclophilin A was used as a loading control to assess equal loading of each 
sample. 
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indicating a level of expression equivalent or greater to the endogenous levels of the IDH protein 
in HEK293 cells. In regards to the IDH2 samples, different band sizes were observed indicating 
the degree of transport into the mitochondria since the mitochondrial leader peptide is cleaved 
after the protein enters the mitochondria. As the protein is being adequately expressed in these 
clones, two clones (the second and third clone also) were kept. The second and third clones of 
each sample were kept and cells will be grown over time to determine how the levels of 5-
methylcytosine and 5-hydroxymethylcytosine change over multiple passages in the 
mitochondrial genome by utilizing the MeDIP technique.  
Effect of Octyl-2-hydroxyglutarate on the 5-hydroxymethylcytosine content of the 
mitochondrial genome 
 As it is known that the production of 2-HG has a pronounced inhibitory effect on the TET 
dioxygenase family and causes a change in the epigenome of mammalian DNA, cells were 
treated with a cell-permeable analog of this oncometabolite, octyl-(D)-2-hydroxyglutarate, to 
determine how it affects the 5-methylcytosine content of the mitochondrial genome, specifically 
the 12S and 16S ribosomal regions. Mutant IDH also oxidizes NADPH to NADP
+
 thereby 
decreasing the stores of NADPH available in the cell. This may be detrimental to the cell as 
NADPH is necessary for many cellular processes such as macromolecular biosynthesis and 
antioxidant properties.  In all tumor samples analyzed to date, the IDH mutations solely produce 
the D-isoform of 2-HG so this experiment should replicate what is found in vivo. This analog is 
able to penetrate both the cell and mitochondrial membranes and would be expected to affect 
processes in all compartments. Also, using this molecule, we bypass any adverse effects of an 
imbalanced NADPH/NADP+ ratio on the mitochondria with respect to oxidative 
phosphorylation and energy production. HEK293 cells were treated with either 1µM or 10µM 
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octyl-(D)-2-HG and DNA was harvested for MeDIP analysis. We included a no drug and DMSO 
control, since the octyl-2-HG is dissolved in DMSO. After MeDIP, endpoint PCR was performed 
to obtain a visual representation of how the different levels of 5mC and 5hmC appear in the 
mitochondria using primer sets for the 12S and 16S rRNA regions of the genome (Figure 3-14). 
Results of endpoint PCR were similar to past examples in that the 5hmC signal was much greater 
compared to its IgG rabbit control while the 5mC signal remained difficult to distinguish from 
the signal generated by the IgG mouse control. 
When analyzed using qPCR, the level of 5-hydroxymethylcytosine decreased by about 
50% in the 12S rRNA region and almost 90% in the 16S rRNA region (Figure 3-15) in samples 
treated with octyl-2-HG as compared to the untreated controls. The DMSO control also had 
reduced 5hmC content in the mitochondrial genome indicating an effect of this molecule on 
mitochondrial epigenetics. Interestingly, the level of 5hmC remained constant even after a ten-
fold increase in octyl-(D)-2-HG concentration suggesting that TET enzymes can be inhibited 
fairly easily by this metabolite at low concentrations and that the concentration of this molecule 
is tightly regulated in cells. The decrease in 5hmC produced by this drug is similar to that 
produced by the mutant IDH proteins implying that the amount of 2-hydroxyglutarate necessary 
for inhibition of TET enzymes that locate to the mitochondria is between 1-10µM and can 
produce an effect on mitochondrial epigenetics fairly quickly. 
 The effect of the cell permeable analog of 2-hydroxyglutarate on 5mC levels in HEK 
293 cells was again difficult to assess, due to the high and very variable background signal seen 
with the mouse IgC antibody control, (Figure 3-16) in both the 12S and 16S regions of this 
genome. Also of note, is that the DMSO vector control, which has a negative effect on 5hmC 
content in the mitochondria, may also have an effect on 5mC levels in the organelle although the  
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12S
16S
Figure 3-14: Visual representation of 12S and 16S rRNA regions after treatment with cell 
permeable 2-hydroxyglutarate. Example of endpoint PCR of immunoprecipitated DNA from 
HEK293 cells after treatment with 1µM octyl-(D)-2-hydroxyglutarate. Both the 12S and 16S 
rRNA regions of the mitochondrial genome were analyzed using specific primers. The 200bp 
amplicon was resolved on a 1% agarose gel. 
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A.  
 
B.  
 
Figure 3-15: Treatment of HEK293 cells with cell permeable 2-hydroxyglutarate results in 
reduced 5hmC content in the mitochondrial genome. 12S (A) and 16S (B) rRNA gene 
regions were analyzed after treatment with 1µM and 10µM concentrations of octyl-(D)-2-HG. 
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Figure 3-16: Treatment of HEK293 cells with cell permeable 2-hydroxyglutarate results in 
indeterminate changes in 5mC content in the mitochondrial genome. 12S (A) and 16S (B) 
rRNA gene regions were analyzedafter treatment with 1µM and 10µM concentrations of octyl-
(D)-2-HG. 
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signal produced is below the IgG baseline value making any comparison impossible. This 
experiment provides clear evidence that 2-HG causes a competitive inhibition of the enzymes 
necessary for hydroxymethylation of the mitochondrial genome. However, an effect of the 
oncometabolite on cytosine methylation of the mitochondrial genome is still an open question. 
Use of an IDH1 Mutation Inhibitor to Rescue 5-hydroxymethylcytosine levels 
 To more fully understand the effect of IDH mutations in tumorigenesis and to determine 
if the effects can be reversed and used as a clinical therapeutic, a company headquartered in 
Cambridge, Massachusetts (Agios) developed a molecule that can specifically inhibit the IDH1 
R132H mutation and restore cellular differentiation potential and nuclear epigenetic marks while 
not affecting IDH1 wild-type tumors (62). As the molecule developed by Agios to inhibit IDH2 
was created against the IDH2 R140Q mutation, our studies focused on the IDH1 mutant inhibitor 
which is specific for the R132H mutation (80). If the new activity of mutant IDH, which 
produces 2-HG, is responsible for a reduction in 5hmC in the mtDNA, we would expect that 
specific inhibition of this activity would restore levels of 5hmC in the mitochondrial DNA. 
Accordingly, we tested whether a similar result could be achieved in mitochondrial DNA and 
restore the level of 5hmC in this genome thereby relieving inhibition of the TET enzymes by 2-
HG. AGI-5198 (5µM) was incubated with HEK293 cells that stably express the IDH1 R132H 
mutation. Drug treated cells were harvested at different time points and pelleted for DNA 
purification to determine the effects of this drug on the mitochondrial epigenetics of the cell. An 
untreated and DMSO treated sample were used as controls for this experiment. Afterwards, 
MeDIP was performed to harvest all of the DNA molecules that contain either 5-methylcytosine 
or 5-hydroxymethylcytosine residues. After MeDIP, endpoint PCR using primer sets for the 12S 
and 16S rRNA regions of the mitochondrial genome was performed to determine the success rate 
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of the IP prior to proceeding to qPCR.  An example of the end-point PCR is shown in Figure 3-
17. Once again, the signal produced by the 5hmC sample was much more apparent than its IgG 
rabbit control while the level of 5mC in the mitochondrial ribosome genes remained diminished 
and close to the level of the IgG mouse control. It is apparent that levels of methylation in the 
two ribosomal regions of the DNA are kept at a minimal level while hydroxymethylation 
remains high in these areas.  
qPCR was employed as before to determine if the quantity of 5hmC residues in the 
mitochondrial genome increases after treating cells with AGI-5198. Treatment with this drug 
does in fact result in an increase in 5hmC content in the 12S and 16S region of mtDNA (Figure 
3-18). In the 16S rRNA region, there is a time-dependent response to the IDH1 mutant inhibitor 
as the level of 5hmC rises above the level of the no-drug control when exposed to this drug for 
short (48 hours) and long (144 hours) periods of time.  In the 12S rRNA region, a positive trend 
exists between 5hmC levels and time exposed to AGI-5198. However, it is interesting to note 
that when evaluating the 12S region, the percentage of the 5hmC modification is greater than 
either of the treated samples indicating a possible technical problem with this assay. Cells used 
for the no-drug control will need to be analyzed to determine if the IDH1 mutation is expressed 
appropriately.   
The level of 5-methylcytosine content was also measured in these AGI-5198 treated cells. 
As seen in Figure 3-19, this drug has an inverse effect on the level of 5mC in the mitochondrial 
genome. When treated with AGI-5198 over time, the level of 5mC in the 12S rRNA region 
decreases to that of the IgG control. This pattern is similar to that seen in the IDH1 wild-type 
transfected cell samples, indicating that the levels of 5-methylcytosine in the 12S region are kept 
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Figure 3-17: Visual representation of 12S and 16S rRNA regions after treatment with 
IDH1 mutant inhibitor. Example of endpoint PCR of HEK293 cells used in experiment to 
determine how AGI-5198 affects mitochondrial epigenetics. Both the 12S and 16S rRNA regions 
of the mitochondrial genome were analyzed using specific primers. The 200bp amplicon was 
resolved on a 1% agarose gel. 
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Figure 3-18: Evaluation of levels of 5hmC after exposure to a specific inhibitor of mutant 
IDH1. IDH1 mutant expressing cells were treated with AGI-5198 for 48 or 144 hours to 
determine if levels of 5hmC could be restored in the mitochondrial 12S (A) and 16S (B) rRNA 
regions.  
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Figure 3-19: Evaluation of levels of 5mC after exposure to a specific inhibitor of mutant 
IDH1. IDH1 mutant expressing cells were treated with AGI-5198 for 48 or 144 hours to 
determine if levels of 5mC could be reduced in the mitochondrial rRNA regions. Both the 12S 
(A) and 16S (B) regions were analyzed. 
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at a minimal level. In the 16S rRNA region, all the treated samples are below their respective 
IgG controls making it difficult to determine if a correlation exists between IDH1 mutant 
inhibition and the level of 5mC in the mitochondria. As the level of 5mC is so low in the no-drug 
treated controls, it is possible that the cells used did not accurately express the IDH1 R132H 
mutation and will need to be analyzed to determine expression of this enzyme in this cell line. 
These results indicate that with the addition of the IDH1 mutant inhibitor AGI-5198 to cells 
expressing this aberrant enzyme, the level of 5hmC can begin to be restored to IDH1 wild-type 
levels with a simultaneous decrease in the level of 5mC over time. This compound inhibits the 
oncogenic function of mutant IDH1in producing 2-HG from α-ketoglutarate, thereby relieving 
inhibition of TET enzymes and allowing for adequate hydroxylation of 5-methylcytosine 
residues in the mitochondrial DNA.  
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Chapter 4: Discussion 
Aberrant Metabolism in Cancer: Understanding the Warburg Effect 
 In the 1950s Dr. Otto Warburg published his seminal paper on the theory of aerobic 
glycolysis in cancer, which stated that cancer cells preferentially produce ATP via lactate 
production in the glycolytic pathway instead of using the oxidative phosphorylation pathway 
typically used by differentiated cells (81). Since then, much work has been done to try to 
understand this hypothesis.  
 In normal cells, ATP is commonly produced via the electron transport chain (ETC) found 
exclusively in the inner membrane of the mitochondria, the “powerhouse” of the cell (Figure 4-
1). This process utilizes NADH, NADPH and FADH2, known electron acceptors produced via 
the tricarboxylic acid cycle, to carry electrons to the different complexes of the ETC. These 
electrons are produced via dehydrogenase reactions in the mitochondria in the form of a hydride 
ion (H
-
). The dehydrogenase reaction receives two hydrogen atoms from its substrate, the 
hydride ion just mentioned and a hydrogen ion (H
+
) which is fluxed out of the mitochondrial 
inner membrane. The electrons produced are carried between the electron acceptors of the five 
complexes of the oxidative phosphorylation chain where they end up combining with O2 to 
create a water molecule. Three of the five complexes (Complex I, III, and IV) subsequently 
produce a hydrogen ion gradient as electrons are passed through the ETC. This proton gradient is 
utilized by the fifth complex in the electron transport chain, ATP Synthase to produce ATP from 
ADP and inorganic phosphate (Pi). This process is typically regulated by the ADP/ATP ratio 
available as a measure of energy demands for the cell.  
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Figure 4-1: Diagram of oxidative phosphorylation as it occurs in normally dividing cells 
within the inner membrane of the mitochondria. NADH is produced via the TCA cycle and 
shuttled to Complex I where electrons are moved to differing complexes to create a proton 
gradient. Proton gradient is utilized in the generation of ATP by Complex V (ATP Synthase). 
Figure adapted from Readnower, 2011.
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 In cancer, cells use a different pathway to achieve rapid ATP production. This pathway, 
termed aerobic glycolysis, utilizes the glycolytic pathway to convert glucose into lactate. In 
normal cells, this pathway operates in a hypoxic environment when energy demands are high 
such as in strenuous exercise. Although glycolysis is much faster at producing ATP, less ATP is 
produced (36). Cancer cells typically utilize this pathway for faster energy production, even in 
the presence of oxygen, to maximize tumor growth. While it is debated as to why this shift in 
ATP production occurs, the rapid uptake of glucose by cancer cells has been employed as a 
clinical tool in tumor screening and detection. [
18
F]fluorodeoxyglucose positron emission 
tomography imaging, or FDG-PET, has been used to detect areas of high glucose uptake in the 
body by using radioactively labeled glucose analogs and has proved highly effective in detecting 
and monitoring tumors.  
 A shift to aerobic glycolysis in cancer cells is usually accompanied by a reduction in 
OXPHOS, achieved through unknown mechanisms. Thus, identifying oncogenic processes that 
directly affect mitochondrial function in general and oxidative phosphorylation in particular are 
critical to our understanding of these complex metabolic reprogramming events. As described in 
this thesis, we have begun a study aimed at understanding whether the production of the 
oncometabolite, 2-hydroxyglutarate, as a result of a gain-of-function mutation commonly found 
in different tumors, plays a role in reprogramming metabolism through modification of the 
mitochondrial genome. 
Role of Mitochondria in disease 
Dr. Warburg also postulated that the mitochondria found in cancerous cells are abnormal 
and become dysfunctional leading to alterations in the energy producing pathway of these cells. 
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While much study has been put into understand the energy portion of the Warburg effect, 
understanding of the mitochondrial aspect of his theory has remained somewhat lacking over the 
past few decades and continues to be controversial as some reports claim that mitochondrial 
function remains normal after tumorigenesis and OXPHOS is uninterrupted (Ward & Thompson, 
2012).  
The endosymbiotic theory states that the mitochondrial genome developed from a 
bacterial species that was engulfed by a primitive eukaryotic cell and which has retained a key 
role in ATP production in eukaryotes to this day. While most of the genetic material encoded by 
this ancestral endosymbiont has been transferred to the eukaryotic nuclear genome, several key 
enzymes remain encoded on the mitochondrial genome, along with rRNAs and tRNAs required 
for mitochondrial transcription and translation, which more closely resembles that of 
prokaryotes. The human mitochondrial genome, as mentioned earlier, is 16.6 kilobases in length 
and encodes 13 proteins integral to the function of the electron transport chain and therefore 
generation of ATP in the cell. Of these thirteen proteins, 7 are included in Complex I, 1 is 
included in Complex III, 3 are part of Complex IV and 2 are found in Complex V. One reason 
why these 13 proteins are retained on the mitochondrial genome is that they are highly 
hydrophobic and are difficult to import into the mitochondria from the nucleus. Another proposal 
of this theory is that these proteins are vital to the metabolic control of the cell and are thus 
regulated by the redox status of the cell (3) which is further emphasized by the relationship that 
exists between reactive oxygen species production and mitochondrial dysfunction.  
The remaining proteins required for oxidative phosphorylation are encoded on the 
nuclear genome, pointing to a need for coordinate control of gene expression between 
mitochondria and nucleus. Epigenetic mechanisms are critical for regulation of gene expression 
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in the nucleus. Mitochondrial epigenetic mechanisms, recently described by our laboratory (68) 
have been implicated in altering mitochondrial gene transcription, and others have suggested a 
role for epigenetics in a retrograde signaling capacity between mitochondria and nucleus (69). 
These proposed interconnections led us to hypothesize that cancer related mutations in genes 
involved in intermediary metabolism, might play a role in dysregulating the balance between 
nuclear and mitochondrial gene expression (48).  
During oxidative phosphorylation, electron carriers found in Complex I and Complex III 
are able to pass an electron to an O2 molecule creating the superoxide free radical 
.
O2
-
. This free 
radical is highly reactive and can produce the hydroxyl free radical 
.
OH as well which can 
damage metabolic enzymes, membrane lipids and nucleic acids. To keep free radical 
concentrations low, cells utilize the superoxide dismutase enzyme to convert these reactive 
oxygen species to oxygen and hydrogen peroxide which is then converted to water and rendered 
harmless by the glutathione peroxidase enzyme. Unfortunately, in some instances, ROS 
production is elevated beyond the level that these enzymes can control and can have serious 
pathologic effects on mitochondria function. Also of importance is that the mitochondrial DNA 
polymerase (mtPOLG) lacks a superb proofreading ability so that mutations in the mitochondrial 
genome arise over time (75). These two problems can lead to mitochondrial dysfunction, and can 
cause muscle weakness, decreased psychomotor skills and decreased bone density, signs typical 
of the ageing process. This buildup of ROS species and mitochondrial mutations has been 
implicated in various neurodegenerative diseases as well in Alzheimer’s disease, Parkinson’s 
disease, and Huntington’s disease. 
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Transcription of the Mitochondrial Genome 
While the 13 protein-coding genes are integral to the oxidative phosphorylation pathway, 
the mitochondrial genome also encodes 2 ribosomal RNAs and 22 transfer RNAs. Early in vitro 
studies performed in human cells using 5’ and 3’ end labeling of mitochondrial transcripts 
showed that two separate polycistronic messages are encoded on the mitochondrial heavy strand 
while one message is encoded on the light strand of the genome (53). One message encodes the 
two ribosmomal RNA genes, 12S and 16S, from a promoter termed HSP1 (Heavy Strand 
Promoter), located 16 base pairs upstream of the gene that encodes the phenylalanine-specific 
tRNA. In fact, the rRNAs are transcribed 10 to 30 more often than the protein-coding genes in 
the mitochondrial genome. These ribosomal components assist in the translation of the protein-
coding genes which are transcribed from the second start site, HSP2. This promoter initiates 
transcription near the 5’ end of the 12S rRNA gene and encodes essentially the entire heavy 
strand. A third message is initiated on the light strand from promoter LSP (Light Strand 
Promoter) that leads to the generation of short transcripts that act as primers in DNA replication, 
as well as a polycistronic mRNA that encodes the ND6 protein, a component of Complex I, and 
multiple tRNAs (20). Processing of these transcribed messages is proposed to take place via the 
tRNA punctuation model. This model suggests that tRNA secondary structures, within 
polycistronic mRNAs, act as molecular punctuation marks to signal for endonucleolytic cleavage 
before and after the tRNA messages where the protein-coding genes reside (57).  
Mitochondrial gene transcription is regulated by genes encoded in the nucleus which give 
rise to the mitochondrial RNA polymerase (POLRMT), mitochondrial transcription factors B1, 
B2 and A (TFB1M, TFB2M and TFAM respectively) and mitochondrial termination factor 
(mTERF). These factors work together to initiate transcription in a site-specific and species-
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specific manner. Much work remains to determine how these proteins interact exactly with the 
mitochondrial genome. One study aimed at uncovering the role of mTERF, found that this 
protein can initiate and terminate transcription of the rRNA transcript by binding the DNA at 
both the HSP1 promoter and at the end of the 16S rRNA gene causing a looping out effect of the 
rRNA genes, and allowing for the recycling of the transcription apparatus.  
A single mitochondrion in a human cell contains, on average, five mitochondrial 
genomes while each cell can contain anywhere from 100 to 1000 mitochondria (64), with 
cultured human cells containing an estimated 8000 mtDNA genomes (13). These mitochondrial 
genomes allow for a more fine-tuned response to environmental stimuli outside and within the 
cell and make it possible to respond very rapidly to stimuli such as growth and division where 
energy requirements are high. Packaging of multiple genomes in the mitochondria is achieved by 
the TFAM transcription factor, as well as mtSSB and Twinkle helicase (22), proteins necessary 
for mitochondrial DNA replication which occurs independently of nuclear DNA replication. This 
packaging produces small structures called nucleoids which are tethered to the mitochondrial 
inner membrane and act in much the same way as histones do for nuclear DNA as TFAM is 
integral to mitochondrial DNA transcription and replication (19).  
The research presented in this thesis was carried out to determine if the production of the 
oncometabolite, 2-HG, had an effect on mitochondrial function via an altered epigenetic pattern. 
Effective transcription of the mitochondrial genome through proper epigenetic modifications 
could possibly be necessary to carry out metabolic processes in the cell and transcription of the 
mitochondrial genome will be studied in future experiments to determine if this is the case. In 
this thesis, we have proposed a novel function of 2-HG in affecting the 5-hydroxymethylcytosine 
levels of the mitochondria which may lead to altered mitochondrial gene transcription impairing 
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cellular metabolism. This work will assist in determining the function of 5-
hydroxymethylcytosine in the mitochondria and determine how the level of this modification 
affects mitochondrial gene transcription and metabolic function.  
Discovery of a novel oncogene: Isocitrate Dehydrogenase 
  In an effort to determine genetic alterations in glioblastoma, one of the most aggressive 
and most common brain cancers in humans, DNA sequencing has been employed to determine 
which genes of the genome become mutated and act as tumor suppressors or oncogenes. At the 
time, one gene of interest that became mutated recurred over and over again in multiple tumor 
samples, the gene that encodes the Isocitrate Dehydrogenase 1 enzyme, a key enzyme of the 
TCA cycle. The most commonly found mutation of IDH1 was found to affect an arginine residue 
in the active site of the enzyme (59). In fact, almost all of the grade II/III gliomas as well as 
many secondary glioblastomas contained a mutation in the active site of the IDH1 enzyme, the 
enzyme that locates to the cytoplasm and peroxisomes of the cell. This mutation of IDH1, which 
converts the molecule isocitrate into α-ketoglutarate, a metabolite necessary for many cellular 
processes, was found to be heterozygous, with retention of a wild type allele, and therefore 
proposed to be autosomal dominant. This mutation was originally thought to result in a buildup 
of precursor molecules in the cell much the same way as the loss of function mutations found in 
the Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) enzymes. FH and SDH occur 
in a single allele in the germline and tumors show a loss of heterozygosity with loss of 
expression of the remaining allele, producing tumors functionally null in these enzymes (89). 
When mutated, these enzymes lead to a buildup of precursor molecules, fumarate and succinate, 
which stabilize the HIF-1α protein and promote angiogenesis. These enzymes are also proposed 
to be inhibitory to α-ketoglutarate enzymes as well. IDH2, the mitochondrial isoform of this 
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enzyme, was also found to be mutated in many brain cancers as well in acute myeloid leukemia. 
Of particular interest is the fact that IDH1 and IDH2 mutations have been shown to be mutually 
exclusive of each other and do not occur simultaneously in the same sample leading many to 
propose these mutations have a similar function (21). They are also mutually exclusive to TET2 
mutations. When analyzed, these IDH mutations were found to be heterozygous and retain a 
wild-type allele while the other is mutated. To date, no IDH mutations have been reported to be 
homozygous. This heterozygous nature has prompted many to speculate that these IDH enzymes 
may act as oncogenes and that these mutations result in a novel gain of function. This 
speculation was supported when levels of a metabolite, 2-hydroxyglutarate, were found to be 
dramatically increased in glioblastoma cells in vitro when mutant IDH1 was expressed (15).  
 In normal human cells, the concentration of 2-HG in the cell is maintained at an 
extremely low level around 0.1nM. This molecule is a by-product of a transhydrogenase reaction 
and is usually converted to α-ketoglutarate fairly quickly by 2-hydroxyglutarate dehydrogenase, 
a nuclear encoded protein. When these 2-HGDH enzymes become mutated, 2-HG builds up in 
the cell and results in a disease termed 2-hydroxyglutaric aciduria which can lead to mental 
retardation, leukoencephalopathy, and a decline in psychomotor skills. In IDH mutant patients, 
the levels of 2-HG in serum can rise from 0.1nM to between 1 and 30mM (17) and the (D)-
isoform of this metabolite is solely produced which is typical of most enzymatic reactions. 
Experiments using the (L)-isoform of this metabolite have shown that it is actually a stronger 
inhibitor of α-ketoglutarate dependent enzymes than the (D)-isoform and is more potent in 
disrupting histone demethylases’ as well as TET enzymes’ normal functions (86).  
 When 2-hydroxyglutarate is allowed to build up in the cell, the oncometabolite 
competitively inhibits the enzymes that utilize α-ketoglutarate to function much in the same way 
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that the buildup of fumarate and succinate can lead to decreased enzymatic activity of these 
enzymes. Production of 2-HG by mutant metabolic enzymes such as IDH, can also lead to 
reduced levels of α-ketoglutarate as this molecule is a common analog of the necessary 
metabolite. To date, more than 70 different enzymes utilize α-ketoglutarate as a substrate. These 
enzymes include prolyl hydroxylases, histone modifying enzymes, as well as DNA 
methylcytosine dioxygenases and other α-ketoglutarate dependent enzymes which can have a 
profound effect on gene expression. The activity of prolyl hydroxylases was inhibited following 
the introduction of IDH2 mutations in cell culture models leading to greater stability of their 
target molecule, HIF-1α. Consequently, when IDH2 is mutated, stem/progenitor cell marks (C-
kit) increase while markers indicative of mature hematopoietic cells (Gr-1 and Mac-1) became 
reduced in the cell indicating a profound effect on cellular differentiation by the competitive 
inhibition of these enzymes by 2-hydroxyglutarate (21). Mutant IDH enzymes also impair 
histone demethylation in a 2-HG dependent manner and have increased levels of repressive 
histone modifications such as H3K9me3 leading to a block in cellular differentiation (49). 
Inhibition of DNA-modifying enzymes also occurs when 2-hydroxyglutarate is elevated in the 
cell.  Of these enzymes, the Ten-eleven Translocation (TET) proteins are integral members 
which catalyze the conversion of 5-methylcytosine residues in the nuclear genome to 5-
hydroxymethylcytosine (72). This novel cytosine modification has been thought to be integral to 
the DNA demethylation pathway as it can further oxidize modified cytosine residues to 5-
formylcytosine and 5-carboxylcytosine. Utilizing AID deamination and the base excision repair 
pathway, this carboxyl modification can be converted to an unmodified cytosine base.  
The TET family of enzymes, of which there are three members, utilize Fe
2+
, O2 and α-
ketoglutarate to catalyze the conversion of 5mC to 5hmC and can subsequently continue to 
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oxidize the 5hmC modified base to 5-formylcytosine and finally 5-carboxylcytosine which can 
then be deaminated to thymine and removed via the base excision repair machinery of the cell 
(32, 26). This active DNA demethylation pathway has been proposed as a way of removing the 
methylation marks on cytosine residues of transcriptionally repressed promoters and may 
therefore lead to the re-expression of silenced genes. As the TET enzymes require α-
ketoglutarate, it has been proven that a surplus of 2-hydroxyglutarate can competitively inhibit 
these enzymes, as well as possibly reduce the pool of α-ketoglutarate available within the cell, 
leading to a decline in the amount of 5-hydroxymethylcytosine residues present in the nuclear 
genome and a consequent rise in the abundance of genomic 5-methylcytosine. This results in the 
establishment of the CpG island hypermethylator phenotype (CIMP) in these IDH mutant 
samples (21, 76).  
Other effects of (D)-2-hydroxyglutarate production by mutated IDH proteins have been 
determined to affect other aspects of the cell. When IDH1 is mutated, studies have shown that 
collagen maturation is impaired due to inhibition of collagen proline-hydroxylases which also 
may act as tumor suppressors in B-cell lymphomas. DNA repair enzymes also seem to be 
affected by 2-HG as well as RNA demethylases that regulate cellular metabolism.  
The predicted role of mutant IDH in human mitochondria 
Recently, the Taylor lab identified the presence of the DNMT1 maintenance 
methyltransferase in the mitochondria, translocated using a mitochondrial targeting sequence 
(MTS) encoded from an upstream start codon. The presence of a MTS was conserved among 
mammalian species, and was shown to translocate a heterologous protein (GFP) into the 
mitochondria. This finding helped to solidify the fact that cytosine modifications can exist in the 
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mitochondria as well as in the nucleus in the context of CpG sites in the mitochondrial genome 
by a mitochondrial isoform of DNMT, mtDNMT1. Interestingly, this mtDNMT1 isoform is up-
regulated by PGC1α and NRF1, necessary molecules for the oxidative stress response and for 
mitochondrial biogenesis (65, 84), and down-regulated by p53, a tumor suppressor gene mutated 
in over 50% of all human tumors. Loss of p53 function in cells leads to a modest 3-fold increase 
in total DNMT1 transcript but a 6-fold increase in the abundance of mtDNMT1 gene transcript. 
Through the use of the MeDIP technique as well as the β-glucosyltransferase assay used to 
detect 5-hydroxymethylcytosine in DNA, it was determined that 5-hydroxymethylcytosine, as 
well as 5-methylcytosine residues are present in the mitochondrial genome (68). Furthermore, 
increased expression of mtDNMT1 resulted in a gene-and-strand specific alteration in 
mitochondrial transcription. The conservation of the enzymes and modifications resulting from 
their action within mitochondria has led to the hypothesis that mitochondrial gene transcription 
might be regulated through epigenetic mechanisms.  
With this information, the research described in this thesis was undertaken to determine 
whether mutant IDH1, IDH2 or both isoforms have any effect on the patterns of methylation and 
hydroxymethylation found in the human mitochondrial genome. As is shown in Chapter 3, when 
either the IDH1 or IDH2 mutant enzymes are transfected into human cell lines, a phenomenon 
similar to that seen in the nucleus is found in regards to hydroxymethylation most likely through 
the inhibition of TET enzymes by 2-hydroxyglutarate. After 48 hours, we show that expression 
of mutant IDH1 or IDH2 causes a substantial decline in the level of 5-hydroxymethylcytosine to 
about 40-50% that of the wild-type IDH transfected samples. For the experiments performed in 
this thesis, both the 12S and 16S rRNA gene regions were first analyzed to determine if mutant 
IDH affects levels of modified cytosine residues in the mitochondria. This effect is most notable 
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within the 12S ribosomal RNA region of the mitochondrial genome, but less apparent in the 16S 
rRNA region of the genome where levels of 5hmC may remain unchanged or even increase in 
the presence of IDH mutations. Future studies investigating the other mitochondrial genes will be 
performed to see if a similar trend is produced across the entire mitochondrial genome after 
mutant IDH is expressed. It is possible to infer that when IDH1 or IDH2 are mutated in human 
cell cultures, the levels of 2-hydroxyglutarate produced by these mutations rise above their 
normal cellular levels and competitively inhibit the TET enzymes as the experiments performed 
in this thesis were done exactly the same as those reported earlier (86, 21). This inhibition in the 
active site of the enzyme results in fewer 5-hydroxymethylcytosine residues converted from 
existing 5-methylcytosine residues in the mitochondrial genome. Impressively, these levels of 
5hmC are reduced fairly quickly, after only 48 hours post-transfection, with mutant IDH, 
showing that the effects of IDH mutants can be felt in the mitochondrial genome extremely 
rapidly and suggesting that the stores of α-ketoglutarate are under tight control within the cell. 
Also of interest is that when these mutant IDH isoforms are co-transfected with the D-isoform of 
2-hydroxyglutarate dehydrogenase (2-HGDH), the levels of 5hmC begin to rise back to the 
levels seen in IDH wild-type transfected samples showing that this enzyme can relieve the 
inhibition on the TET enzymes by the 2-HG oncometabolite, presumably through conversion of 
2-HG to α-KG. While rescue is clearly observed in the IDH1 transfected samples, the levels of 
5hmC found in the IDH2 mutant transfected samples tend to decrease when co-transfected with 
the D-2HGDH enzyme. To accurately determine how this enzyme affects 2-HG levels, mass 
spectrometry should be employed to measure the level of this oncometabolite after co-
transfection of (D)-2HGDH. As α-ketoglutarate is not as limited in the mitochondria as it is in 
the nucleus, the level of 2-HG produced by this mutation could be substantially larger than that 
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produced by the IDH1 mutant enzyme and should be measured using mass spectrometry to 
accurately determine the levels of this metabolite in the cell. In fact, reports have demonstrated 
that the concentration of 2-HG is much higher in IDH2 mutated samples than IDH1 mutant 
samples which may possibly be saturating the 2-HGDH enzyme which can travel between the 
mitochondria and cytoplasm.  
 While the effects of IDH mutation on 5hmC content in the mitochondrial genome can be 
determined fairly easily, how IDH1 and IDH2 mutant enzymes affect the levels of 5-
methylcytosine in the rRNA regions of the genome is less clear. As a result of the decrease in 
5hmC seen in these transiently transfected cells, we expected to see a concomitant increase in 
5mC. As can be seen from the results in Chapter 3, when IDH1 mutant enzymes are introduced 
into HEK293 cells, the level of 5-methylcytosine in these samples increases in both the 12S and 
16S regions of the genome. However, in the IDH1 and IDH2 wild-type samples, the levels of 
5mC are well below the 5mC levels of their respective IgG mouse control levels which is used as 
a measure of baseline. When analyzing the IDH2 R172K mutation, the levels of 5mC, as a 
measure of percentage of input, in both the 12S and 16S region decrease below the IgG mouse 
control which is opposite to the effect this mutation has on the nuclear genome. There are several 
technical factors that could contribute to the inconclusive nature of these results. The 
performance of the mouse IgG control antibody shows a very high degree of batch-to-batch 
variability. We have tested two different lots of mouse IgG. The first lot consistently gave 
backgrounds that were substantially above 5mC antibody signal. The control IgG used in the 
experiments described in this thesis was somewhat better in performance, but still gave higher 
background than those previously reported (68). Others have reported that alterations in nuclear 
5mC, as a result of transfection with IDH mutants, occur slowly over many cell generations (76). 
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We have accordingly isolated clones of stably transfected cells expressing varying levels of 
mutant IDH proteins to determine whether a similar phenomenon occurs in the mitochondrial 
genome. Co-transfection of the IDH1 mutation with the D-2HGDH enzyme leads to a decrease 
in the levels of 5mC content when analyzing the 12S and 16S rRNA regions, while co-
transfection of the IDH2 mutant enzyme leads to an increase in 5mC content. With this 
confounding evidence, it is difficult to determine how IDH mutations affect the 5-methylcytosine 
levels of the mitochondrial genome. Recently, a positive correlation has been determined 
between mutant IDH1 and p53 expression as lower grade gliomas, which typically harbor the 
IDH1 R132H mutation, also show an increase in p53 levels which is a commonly mutated 
protein found in cancers (7, 73). This interaction seems to provide evidence that mitochondria 
are integral to cell cycle progression (40) although the functional significance of this interaction 
remains to be determined. With the evidence produced by the Taylor lab regarding the effects of 
p53 on mtDNMT1 transcription, it is probable that a connection exists between mutant IDH and 
mtDNMT1 expression. Future studies will determine how mutant IDH affects the expression 
level of mtDNMT1 to find if a connection truly exists between this oncogene and the 
methylation machinery of the mitochodnria. 
 To better understand how and if the mitochondrial rRNA regions become 
hypermethylated, stable clones were produced that express either the wild-type or mutant 
enzymes of the IDH isoforms. In the nuclear genome, it was determined that hypermethylation of 
both cytosine residues and histone markers does occur slowly over many cell generations when 
mutant IDH is introduced (about 20 passages of HEK293 cells) (49). How these IDH mutations 
may come to affect the mitochondrial genome over time remains to be determined and we are 
currently working to solve this question. Stable clones have been produced and analyzed using 
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immunoblotting techniques. As was shown in Chapter 3, the clones chosen express their 
transfected mutant IDH protein at a level equivalent to or similar to the endogenous levels of 
IDH in HEK293 cells when using an antibody specific for IDH proteins. We have also chosen 
clones that overexpress mutant IDH to varying degrees. Future MeDIPs and hydroxy-MeDIPs 
will be performed at different passages of the cells to determine if the levels of 5-methylcytosine 
rise substantially above baseline in the mitochondrial genome or whether a different effect is 
seen in regards to mitochondrial cytosine modifications when IDH mutant proteins are expressed 
stably within the cell population.  
The Importance of Mitochondrial Cytosine Modifications 
It has been shown that not only is TET2 present in the mitochondria but also the 
enzymatic machinery necessary for the base excision repair pathway indicating a role for 5-
hydroxymethylcytosine in DNA demethylation and gene re-expression in the mitochondria that 
is similar to that found in the nucleus. Also, as mitochondria contain protein-containing nucleoid 
structures that package the DNA with the high-mobility group protein TFAM and other proteins, 
methylation and hydroxymethylation may be integral in the stability of these higher order 
structures and therefore help to control transcription of mitochondrial genes. What’s more, this 
control could be specific to certain mitochondrial genes as changes in gene transcription occur 
differentially in different areas of the genome as a result of changes in mtDNMT1 levels (68). 
These results point toward mitochondrial cytosine modifications as a possible biomarker and 
diagnostic tool for disease (30). 
Studies have determined that Complexes IV and V can also be inhibited by the 
oncometabolite, 2-HG, and lead to superoxide production and decreased cell viability (43). It is 
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possible that this inhibition is caused by methylation of the genes encoding proteins necessary 
for these complexes although further work remains to be done. The effect IDH1 and IDH2 
mutations have on the 12S rRNA region of the mitochondrial genome is intriguing. Methylation 
of this area has been implicated in disease and ageing phenotypes. One epidemiological study 
determined that when workers were exposed to airborne pollutants, methylation levels of the 12S 
rRNA region increased compared to subjects not exposed to these same pollutants (Byun, 2013). 
Another study measured the level of 12S methylation in adult males and found that the 
percentage of methylation in this region decreased with age (Giordano, 2012). While this work 
remains to be replicated, it is interesting that methylation of this region may play such an 
important role in human health and could possibly become a target of therapeutics. By 
comparison, work regarding how methylation of the 16S rRNA region of the mitochondrial 
genome, which is downstream of the 12S region, has been lacking and will require future 
experiments to determine if modification of this rRNA gene is significant to overall 
mitochondrial function.   
Just as important as methylation status and cellular differentiation, mutation of IDH 
enzymes could affect cellular metabolism as well. When mutated, the defective allele of IDH 
utilizes α-ketoglutarate and NADPH to produce 2-hydroxyglutarate. This results in a net 
reduction of available NADPH in the cell decreasing the NADPH/NADP
+
 ratio (Bleeker, 2010). 
This molecule, which functions as an electron acceptor for the oxidative phosphorylation 
pathway, is vital to macromolecular biosynthesis and serves as a powerful antioxidant (37). 
Many anabolic pathways employ NADPH as a co-factor in the synthesis of nucleic acids, protein 
and lipids (10). As mentioned previously, NADPH serves as a co-factor for glutathione reductase 
to clear the cell of harmful free radicals. Dysregulation of the cellular redox status can contribute 
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to cellular transformation and tumorigenesis. Although how this redox status is affected in IDH-
mutant tumors remains to be determined, studies suggest IDH provides a protective role (8, 44).   
Perspectives and Conclusions 
The effects of IDH mutations in the cell are multifaceted. This novel oncogene serves to 
dysregulate both cellular gene expression and differentiation. The involvement of mutant IDH 
and the oncometabolite produced in cellular metabolism is of considerable interest and is the 
focus of work arising from this thesis. Cell culture work has determined that this enzyme, when 
mutated, leads to an increase in a metabolite, (D)-2-HG, which competitively inhibits enzymes 
that utilize α-ketoglutarate in the cell, the metabolite normally produced by IDH (86). This leads 
to increased gene methylation over time via inhibition of TET proteins in the nucleus (76, 21). In 
this thesis, we determined the effect of this oncometabolite on the mitochondrial genome, in 
which cytosine residues have been shown to be both methylated and hydroxymethylated. The 
results obtained clearly show an effect of 2-HG on hydroxymethylation of specific mitochondrial 
genes. Further work will need to be done to determine how this mutated enzyme affects 
methylation levels and how these different methylation patterns affect mitochondrial function 
and mitochondrial gene transcription. As described by Nass, methylation in the mitochondria is 
quite sparse and tightly regulated (54). Also, how NADPH reduction affects cellular metabolism 
will be vital to understanding this enzyme’s function. To determine the functional consequences 
of decreasing 5hmC levels, abundance of mitochondrial transcripts will be analyzed to determine 
if this modification has an effect on gene expression in this subcellular compartment. Also, the 
new XF Analyzer technology developed by Seahorse Bioscience could be utilized to measure 
mitochondrial function in individual cells by determining oxygen consumption and extracellular 
acidification as a function of respiration and glycolysis respectively. If IDH mutations affect 
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gene expression through decreased hydroxymethylation in the mitochondrial genome as well as 
decreasing NADPH stores in this organelle, we would expect that respiration might be less 
effective in cells harboring this mutation. This may thus push cells towards a more glycolytic 
state thereby increasing the amount of lactate produced by the cell since ATP will not be 
produced as rapidly as needed.   
The mitochondrial genome accounts for less than 1% of the total DNA found in human 
cells. However, the information encoded on this genome is integral to the health and viability of 
human cells. While it remains unclear how epigenetic markers affect the mitochondrial genome, 
it is interesting to speculate about the role of both 5-methylcytosine and 5-
hydroxymethylcytosine in both mitochondrial maintenance and transcription. Our work suggests 
an important interplay between epigenetics and the metabolism of the human cell. Dr. Warburg’s 
work, published more than half a century ago, has taken on a new importance as our 
understanding of the relationship between misregulated metabolism and carcinogenesis expands. 
With the work performed in this thesis, we have expanded our understanding of epigenetic 
factors in the mitochondria and opened the way to a greater understanding of the impact of 
aberrant metabolic enzymes on the mitochondrion and the cell. A new area of research into 
mitochondrial epigenetics has been opened linking metabolism and cytosine modification 
together via the mutation of the isocitrate dehydrogenase gene.  
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